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ABSTRACT
Cardiovascular diseases, including atherosclerosis, are the leading cause of death in the
United States. Atherosclerotic lesions are formed by deposition of lipids in the intima of arteries.
Upon exposure to oxidative stresses, low-density lipoprotein (LDL) is converted to highly
atherogenic oxidized LDL (ox-LDL) particles, contributing to disease development and
progression. Advanced disease stages may result in calcification of lesions. This calcification
process is important, as it has been shown to be associated with stable plaques that are less
prone to rupture. Calcification is present in lipid rich domains of lesions, however neither the
composition of the mineralized calcium deposits nor its relationship to lipid peroxidation or the
lipid rich atherosclerotic core has previously been identified. This study provides evidence that
the lipid peroxide derived dicarboxylic acid (DCA), azelaic acid (AzA) induces calcification in
smooth muscle cells, thereby providing the link between calcification and overall plaque burden,
and association of calcification with the lipophilic region of the lesion. The potential of lipid
peroxide-derived lipophilic DCAs to promote calcification upon exposure to vascular smooth
muscle cells was tested. 13-hydroperoxylinoleic acid (HPODE) treatment resulted in the cellular
conversion to 9-oxononanoic acid (ONA) and AzA as determined by mass spectrometry analysis.
Delivery of AzA via lysophosphatidylcholine (Lyso-PtdCho) micelles induced calcification of
human aortic smooth muscle cells (HASMC). AzA was identified in calcified human and mouse
atherosclerotic plaques. Calcification of HASMC due to AzA treatment resulted in a less
inflammatory and oxidative environment as indicated by genetic expression. These results
demonstrate that DCAs may contribute to atherosclerotic calcification thus accounting for the
iii

latter’s relationship to plaque burden and association with lipids. This study also challenges the
dogma that arterial calcification represents the deposition of calcium phosphate and has
implications with the development of new therapeutic strategies in treating late stage
atherosclerosis.

iv

Dedicated to my Loving Family Ashraf, Riham, & Rana

v

ACKNOWLEDGMENTS
First and foremost I must express my utmost gratitude towards my mentor and advisor
Dr. Sampath Parthasarathy. He has given me the support, guidance, and advice necessary to grow
as a scientist, and as an individual. Under his wisdom I have learned so much about science,
management, and life. I am truly grateful to have had the opportunity to work under Dr. Sam, as
he is best mentor one could ever hope to have.
I would like to thank my committee members Dr. Saleh Naser, Dr. Deborah Altomare, and
Dr. Michal Masternak for their support throughout my project.
I would like to thank my lab members, especially Dr. Chandrakala Aluganti Narasimhulu
for giving me a great environment to work in, for guiding me as a growing researcher, and for
giving me friendship at work. I would like to thank my friends in the program, Sarah Gitto, Patrick
Cherubin, and Brian Dow. For without friends we have nothing.
It goes without mention that I am grateful for my parents and my sister, for which this
thesis is dedicated. They have given me an incredible amount of support emotionally and
spiritually, and always were there for me.

vi

TABLE OF CONTENTS
LIST OF FIGURES ............................................................................................................................ xiii
LIST OF ABBREVIATIONS ................................................................................................................ xv
CHAPTER ONE: GENERAL INTRODUCTION...................................................................................... 1
Atherosclerotic Calcification Correlation with Plaque Stability & Vulnerability ........................ 5
Tissues In Which Calcification Has Been Observed .................................................................. 10
Techniques used to detect calcification and their pitfalls ........................................................ 12
CHAPTER TWO: EXPERIMENTAL PROCEDURES ............................................................................ 14
Materials and Reagents ............................................................................................................ 14
Cell Culture ................................................................................................................................ 14
Preparation of HPODE............................................................................................................... 15
Synthesis of 9-Oxononanoic Acid ............................................................................................. 15
Treatment of cells with HPODE/ONA ....................................................................................... 16
LC-MS analysis for in vitro cell culture experiments ................................................................ 16
Thin layer chromatography and autoradiography 14C-HPODE / 14C-ONA ................................ 16
Micelle preparation .................................................................................................................. 17
WST-1 Cell Viability Assay ......................................................................................................... 17
Induction of calcification in HASMCs by AzA ............................................................................ 18
Alizarin Red S Staining............................................................................................................... 18
von Kossa staining ..................................................................................................................... 18
Animals...................................................................................................................................... 19
vii

Collection of Mouse Plasma and Organs .................................................................................. 20
Isolation and Quantification of Mice Aortic Lesions ................................................................. 20
X-Ray Analysis ........................................................................................................................... 20
Isolation Calcified And Non-Calcified Regions of The Human Aortic Tissues ........................... 21
Micro CT Analysis ...................................................................................................................... 21
Initial Protocol for Aortic Tissue Sample Preparation for LC-MS Analysis................................ 22
Revised Protocol for Aortic Tissue Sample Preparation for LC-MS Analysis ............................ 22
LC-MS Analysis .......................................................................................................................... 23
Quantification of AzA ................................................................................................................ 25
Matrix Effect of Tissue Samples ................................................................................................ 25
Extraction Recovery Of AzA From Tissues Samples .................................................................. 26
Calcium and Phosphate Quantification .................................................................................... 26
Alkaline Phosphatase Activity Assay ......................................................................................... 26
Statistical Analysis ..................................................................................................................... 27
CHAPTER THREE: A NOVEL MECHANISM FOR ATHEROSCLEROTIC CALCIFICATION-POTENTIAL
RESOLUTION OF THE OXIDATION PARADOX ................................................................................ 28
Abstract ..................................................................................................................................... 29
Introduction .............................................................................................................................. 31
Results ....................................................................................................................................... 33
Decomposition of lipid peroxides by HASMCs...................................................................... 33
Conversion of ONA to AzA in the presence of α-tocopherol and HASMC ........................... 35

viii

Detection of AzA in tissues ................................................................................................... 38
Identification of calcification in aged ApoE-PON1 double knockout mice ........................... 38
Identification of calcification in human atherosclerotic aortic plaques ............................... 41
AzA quantification in tissue samples .................................................................................... 43
Supplementary Figures ............................................................................................................. 46
Discussion.................................................................................................................................. 54
Innovation ................................................................................................................................. 58
Methods .................................................................................................................................... 59
Materials and reagents ......................................................................................................... 59
Cell culture ............................................................................................................................ 59
Preparation of HPODE........................................................................................................... 59
Synthesis of 9-Oxononanoic Acid ......................................................................................... 60
Treatment of cells with HPODE/ONA ................................................................................... 60
LC-MS analysis for in vitro cell culture experiments ............................................................ 61
Thin layer chromatography and autoradiography 14C-HPODE / 14C-ONA ............................ 61
Micelle preparation .............................................................................................................. 61
WST-1 cell viability assay ...................................................................................................... 62
Induction of calcification in HASMCs by AzA ........................................................................ 62
Alizarin Red S staining ........................................................................................................... 63
von Kossa staining ................................................................................................................. 63
Animals.................................................................................................................................. 64

ix

Collection of plasma and organs ........................................................................................... 64
Isolation and quantification of mice aortic lesions ............................................................... 65
X-Ray analysis ........................................................................................................................ 65
Isolation calcified and non-calcified regions of the human aortic tissues ........................... 65
Micro CT analysis .................................................................................................................. 66
Aortic tissue sample preparation for LC-MS analysis ........................................................... 66
LC-MS analysis....................................................................................................................... 67
Quantification of AzA ............................................................................................................ 69
Matrix effect of tissue samples ............................................................................................. 69
Extraction recovery of AzA from tissues samples ................................................................. 70
Calcium and Phosphate quantification ................................................................................. 70
Statistical analysis ................................................................................................................. 70
Acknowledgement .................................................................................................................... 72
Disclosures ................................................................................................................................ 73
CHAPTER FOUR: INFLAMMATION AND CALCIFICATION – CAN CALCIFICATION BE GOOD? ........ 74
Abstract ..................................................................................................................................... 75
Introduction .............................................................................................................................. 76
Methods .................................................................................................................................... 79
Reagents and Cell culture ..................................................................................................... 79
Micelle Preparation............................................................................................................... 79
Induction of calcification in HASMCs by AzA ........................................................................ 79

x

von Kossa Staining ................................................................................................................ 80
ApoE/PON1 double knockout Mice ...................................................................................... 80
Collection of mouse plasma and organs ............................................................................... 81
Isolation and quantification of aortic lesions ....................................................................... 81
Isolation calcified and non calcified regions of the human aortic tissues ............................ 81
Sample preparation for LC-MS analysis: ............................................................................... 82
LC-MS Analysis ...................................................................................................................... 82
Quantification of AzA ............................................................................................................ 84
Matrix Effect of Tissue Samples ............................................................................................ 85
Extraction Recovery of AzA From Tissues Samples .............................................................. 85
ALP activity ............................................................................................................................ 85
cDNA synthesis and RT-PCR reaction.................................................................................... 86
Statistical analysis ................................................................................................................. 87
Results ....................................................................................................................................... 88
Calcification of Human Aortic Smooth Muscle Cells ............................................................ 88
Effect of AzA induced calcification on HASMC genetic expression ...................................... 89
AzA induced calcification of HASMC inhibits alkaline phosphatase activity ........................ 90
Expression of genes related to calcification in human and mouse aortic samples .............. 91
Discussion.................................................................................................................................. 95
Acknowledgement .................................................................................................................... 99
Disclosures .............................................................................................................................. 100

xi

CHAPTER FIVE: CONCLUSION ...................................................................................................... 101
APPENDIX A: IACUC ANIMAL PROTOCOL APPROVAL LETTERS ................................................... 106
APPENDIX B: IRB PROTOCOL APPROVAL LETTER ........................................................................ 109
APPENDIX C: PUBLICATION REPRINT PERMISSION ..................................................................... 111
REFERENCES ................................................................................................................................ 113

xii

LIST OF FIGURES
Figure 1 – Graphical Representation of AzA Hypothesis .............................................................. 11
Figure 2 – HASMC Decomposition of HPODE and Conversion of ONA to AzA is Inhibited by αTocopherol .................................................................................................................................... 34
Figure 3 – Calcification of HASMC induced by AzA micelle treatment ......................................... 37
Figure 4 – Calcification in aged ApoE-PON1 double knockout mice ............................................ 40
Figure 5 – Calcification in human aortic tissue samples ............................................................... 42
Figure 6 – Human aortic tissue microCT images........................................................................... 43
Figure 7 – The representative LC-ESI-HRMS extracted ion chromatograms. ............................... 44
Figure 8 – Decomposition of HPODE by HASMC. ......................................................................... 46
Figure 9 – Thin Layer Chromatography autoradiograph of the lipid fractions. ............................ 47
Figure 10 – The effect of micelle treatment on HASMC cell viability. .......................................... 48
Figure 11 – HASMC Calcification Positive Control ........................................................................ 49
Figure 12 – ApoE-Pon1 DKO Plasma Lipids Profile. ...................................................................... 50
Figure 13 – Lesion area of ApoE-Pon1 DKO mice. ....................................................................... 51
Figure 14 – Human Aortic Tissue Samples Clinical Diagnosis of Subjects. ................................... 52
Figure 15 – Human Aortic Tissue Samples Quantified Molecules in nmoles. .............................. 53
Figure 16 – Schematic representation of the AzA hypothesis. ..................................................... 57
Figure 17 – Calcification of HASMC .............................................................................................. 88
Figure 18 – Genetic Profile of AzA induced Calcification .............................................................. 90
Figure 19 – Alkaline Phosphatase Activity .................................................................................... 91
xiii

Figure 20 – ApoE/PON1 DKO Gene Expression in Calcified and Non-Calcified Aortic Lesions .... 92
Figure 21 – Detection of Calcification and AzA in Human Aortic Tissue ...................................... 93
Figure 22 – Expression Levels in Human Aortic Tissue ................................................................. 94
Figure 23 – Flowchart of Lipid Peroxide Degradation and Inhibition by Antioxidants ............... 104

xiv

LIST OF ABBREVIATIONS
4-HNE – 4-Hydroxy nonenal
ALP – Alkaline phosphatase
AOX – Aldehyde oxidase
AP – ApoE-PON1
ApoE – Apolipoprotein E
AzA – Azelaic acid
Ca – Calcium
Ca-AzA – Calcium azelate
CHD – Coronary heart disease
CT – Computerized tomography
DCA – Dicarboxylic acid
DKO – Double knockout
EDTA – Ethylenediaminetetraacetic acid
ESI – Electrospray ionization
HASMC – Human aortic smooth muscle cells
HPODE – 13-Hydroperoxyoctadecadienoic acid
IS – Internal standard
LC-MS – Liquid chromatography-Mass spectrometry
LDL – Low density lipoprotein
LOD – Limit of detection
xv

LOQ – Limit of quantification
Lyso-PtdCho – Lysophosphatidylcholine
MPO – Myeloperoxidase
Na – Sodium
Na-AzA – Sodium azelate
ONA – 9-Oxononanoic acid
Ox-LDL – Oxidized LDL
PC – Phosphocholine
PLC – Phospholipase C
PON1 – Paraoxonase 1
PtdCho – Phosphatidylcholine
PUFA – Poly-unsaturated fatty acid
QTOF-MS – Quadrupole time of flight mass spectrometer
sPLA2 – Secretory phospholipase 2
SRA – Type A Scavenger Receptor

xvi

CHAPTER ONE: GENERAL INTRODUCTION
Atherosclerosis is a chronic inflammatory disease characterized by the subendothelial
accumulation and modification of LDL resulting in the aggregation of atherogenic oxidized lipid
species, vessel wall thickening, inflammation, and calcification [1]. Atherosclerosis begins as a
fatty streak, which initiates very early in life. Fatty streaks are formed from the retention of LDL
in the intima, the innermost region of blood vessels, between the single cell layer of endothelial
cells that directly contact blood and the underlying smooth muscle cells. Elevated levels of
circulating LDL results in increased retention of these particles within the intimal region [2]. The
subendothelial accumulation of apolipoproteinB (apoB)-containing lipoprotein occurs typically in
areas of disturbed lamellar flow such as arterial branch points and bifurcations. Commonly
affected blood vessels include the coronary arteries, carotid arteries, and peripheral vessels such
as the iliac artery [3-6].
Persisting LDL within the intimal region is susceptible to oxidative stresses via both
nonenzymatic mechanisms such as free radicals generated by surrounding cells or mediated by
enzymes such as myeloperoxidase, lipoxygenases, and hydrolytic modifications of secretory
phospholipase A2 (sPLA2) [3, 4, 7-10]. Oxidative potential of LDL begins with the loss of the
antioxidant function of vitamin E, followed by the oxidation of polyunsaturated fatty acids
generating lipid peroxides. Further oxidation results in the fragmentation of lipid peroxides
generating breakdown products including aldehydes, that may further modify LDL by covalently
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binding with the lysine residues on apoB, resulting in a modified, atherogenic form of LDL
referred to as oxidized (ox-LDL).
The accumulation of Ox-LDL activates the endothelial cells causing the expression of
proinflammatory factors such as adhesion molecules P-selectin, ICAM1, and VCAM1 and
chemokines such as CCL2, CCL5, and MCP-1, which recruit monocytes to the vessel wall further
perpetuating the disease [11-14]. Ox-LDL also inhibits the chemotactic properties of
macrophages, causing their increased retention within the intima.
Oxidized LDL is the main culprit in foam cell formation, as the macrophage cannot take
up native LDL, which is recognized by the LDL receptor, quick enough to form foam cells due to
down regulation of the LDL receptor in the presence of high native LDL concentrations [3, 6, 15,
16]. The macrophage recognizes ox-LDL via its scavenger receptors, resulting in the uptake of the
oxidatively modified particles. Moreover, macrophages and dendritic-like cells express a variety
of scavenger receptors such as the type A scavenger receptor (SRA), CD36, and CD68 that can
participate in uptake[17-19].
Increased lipid accumulation eventually results in formation of the lipid laden
macrophage foam cell, the hallmark of atherosclerosis [10, 20]. Foam cell accumulation in the
fatty streaks progresses the plaque into an intermediate lesion, characterized by increased
extracellular lipid deposits [21-23]. The lesion progresses into an atheroma as more extracellular
lipid is deposited in the core and begins to disturb the extracellular matrix and arterial structure
[2, 24].
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Advanced atherosclerotic lesions (fibroatheroma) have extensive accumulation of
extracellular lipids within a necrotic, lipid-rich core, and are characterized by the migration and
proliferation of smooth muscle cells (SMC) from the media into the intima. Smooth muscle cells
can also take up modified lipoprotein becoming foam-like cells [24]. A fibrous cap develops
encapsulating the advanced plaque’s necrotic core, the accumulated lipids, cellular debris, and
leukocytes [15]. The core expands due to continued lipid accumulation, SMC migration, and the
necrosis and apoptosis of vascular smooth muscle cells and macrophages. The cellular debris and
ischemic environment often results in the induction of calcium mineralization [2, 24].
Lipid peroxides and their breakdown products have been studied in the context of
atherosclerosis [22]. It is well established that the oxidation of linoleic acid generates toxic and
reactive aldehydes (e.g. ONA), we took this a step further and studied their downstream DCA
oxidized products (i.e. AzA) [25]. Along with this oxidation, the modification of
phosphatidylcholine (PtdCho) on the oxidized LDL particle generates lysophosphatidylcholine
(Lyso-PtdCho) species via the action of sPLA2. This oxidation may occur spontaneously or may be
catalyzed by enzymes such as myeloperoxidase or xanthine oxidase [26].
It has been observed that the DCA AzA is an anti-inflammatory agent that is non-toxic to
humans, and as a result has been used in topical anti-acne creams [25]. Our laboratory has
recently demonstrated that feeding AzA to apoE knockout mice, a well established model of
atherosclerosis, is athero-protective as it reduced macrophage infiltration into atherosclerotic
lesions, resulting in smaller lesion sizes [25].
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The plaque burden is associated with lipid load and calcification due to the deposition of
insoluble calcium minerals [21]. Calcified lesions are regarded as stable plaques due to their
decreased propensity to rupture compared to non-calcified, or vulnerable plaques. Calcification
may thus represent a physiological mechanism of protecting advanced lesions from rupture [27,
28]. Although this process has been studied extensively, neither the mechanism by which it
occurs nor the chemical properties of the deposited minerals have yet been elucidated. More
importantly the link to oxidative stress and its association with the lipid rich milieu of the plaque
remains unknown.
To date, the methods of detecting calcification rely on the analysis of physical properties
via computerized tomography (CT), or on calcium specific stains such as von Kossa and alizarin
red S. Although these techniques excel at detecting a solid calcium mineral, they fail at identifying
the molecular entity to which the calcium is bound. DCAs have the intrinsic chemical capacity to
bind divalent metals and create this calcium complex. Importantly, unlike shorter DCA species
(e.g. malonic acid), which enter the metabolic pathway, AzA is lipophilic due to its longer acyl
chain thus rendering it capable of associating with the lipid-rich necrotic core. Concomitantly, oxLDL derived Lyso-PtdCho can undergo cleavage via phospholipase C (PLC) releasing
phosphocholine (PC) that may also contribute to calcification by increasing the intracellular
concentration of lipid peroxide derived phosphate for binding calcium.
From the inception of the oxidized LDL hypothesis, it has been proposed that lowering
the oxidative potential may ameliorate the progression of atherosclerosis [15, 29, 30]. This
hypothesis has worked in animal models successfully, but has not shared the same success in
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human clinical trials [31-38]. Perhaps the use of antioxidants in treating late stage patients with
atherosclerosis who have already advanced to the stage where their plaques contain extensive
oxidative degradation products, may actually inhibit the oxidation cascade to detoxify aldehydes
into an inert DCA, which actually may exhibit atheroprotective properties [25, 26].

Atherosclerotic Calcification Correlation with Plaque Stability & Vulnerability
Calcification is the deposition and mineralization of calcium resulting in a solid mass akin
to bone for the purpose of structural support or formation of a protective layer. This is an
important physiologic process necessary for the formation of skeletal and dental structural
components, but may form in any soft tissue due to pathological conditions such as
atherosclerosis, chronic kidney disease, osteoporosis, menopause, diabetes, and soft tissue
tumors [39-43].
The biomineralization process typically deposits insoluble calcium salts of variable
chemical composition such as calcium carbonate (CaCO3), calcium phosphate (Ca3(PO4)2), calcium
oxalate (CaC2O4), calcium pyrophosphate (Ca2P2O7), and hydroxyapatite (Ca10(OH)2(PO4)6).
While this can explain the formation of calcium deposits within the context of bone and
teeth, it does not fully explain the formation of these types of complexes within the context of
atherosclerosis. AzA being a medium chain 9-carbon DCA has the intrinsic property of associating
with the lipid rich core of atherosclerotic plaques due, and can bind calcium due to its two
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carboxylic ends, forming a mineralized salt. AzA can help bridge the association of calcified
minerals in the context of atherosclerosis.
Vascular calcification is the deposition of insoluble calcium in one or more layers of the
vessel walls. In the context of atherosclerosis, calcification occurs in the intimal layer of vessels.
Atherosclerosis is a progressive disease of chronic inflammation in the arterial wall due to the
accumulation of modified lipoproteins, monocyte-derived macrophages, T cells, and cellular
components within the intima of the vessel wall [2, 24].
Fatty streaks are highly common and are asymptomatic, but may progress into advanced
lesions characterized by a necrotic, lipid rich core containing foam cells and cellular debris,
surrounded by a fibrous cap of smooth muscle cells and extracellular matrix. Complications of
advanced fibrous lesions include calcification and ulceration into the luminal surface. The
occlusion of the arterial lumen may affect blood flow and eventually may develop into the
formation of a thrombus that potentially leads to myocardial infarction or stroke [3, 4].
Atherosclerosis begins due to the subendothelial accumulation of apolipoproteinB
(apoB)-containing lipoprotein. This accumulation typically occurs at focal sites of arterial flow
where the blood flow is disturbed such as at arterial branch points and bifurcations, such as
coronary arteries, carotid arteries, and in peripheral vessels such as the iliac artery [5, 29]. The
hepatic apoB lipoprotein is very low-density lipoprotein (VLDL), which is secreted into circulation
and eventually converted to the atherogenic low density lipoprotein (LDL). The apoB lipoprotein
of intestinal origin is the chylomicron, which can be converted in circulation to chylomicron
remnants.
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This initiating step of atherosclerosis was demonstrated in a study that utilized LDL that
was modified via site-directed mutagenesis of apoB100 to have a low binding capacity to arterial
proteoglycans, this LDL caused significantly fewer lesions in vivo even under hyperlipidemic
conditions [6]. LDL then enters the intima where it undergoes oxidative modifications by free
radicals and enzymes such as myeloperoxidase or lipoxygenases, and hydrolytic modifications by
secretory phospholipase A2 (sPLA2). The accumulation of modified LDL can activate endothelial
cells causing expression of proinflammatory genes that cause recruitment of monocytes to the
vessel wall such as adhesion molecules P-selection, ICAM1, and VCAM1 and chemokines such as
CCL2, CCL5, and MCP-1 [11-14].
Atherosclerotic plaques begin as fatty streaks in the arterial wall due to accumulation of
lipid laden macrophage foam cells. This deposition results in vessel wall thickening and results in
the loss of elasticity which disrupting cardiovascular hemodynamics, which may cause cardiac
hypertrophy and ischemia, and eventually heart failure.
The atherosclerotic lesion represents a lipid rich inflammatory environment. Elevated
levels of circulating LDL particles result in the increased retention of these particles in the intima
where they are susceptible to oxidation enzymatically via myeloperoxidase, secretory
phospholipase 2 (sPLA2), or lipoxygenases of inflammatory cell origin or nonenzymatically via
reactive oxygen species. Oxidized LDL is recognized by the scavenger receptor of macrophages
causing its uptake [44, 45]. Oxidized LDL is the main culprit in foam cell formation as native LDL,
which is recognized by the LDL receptor, is not taken up by macrophages fast enough due to the
down regulation of the LDL receptor. Macrophages and dendritic-like cells internalize oxidized
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LDL recognized via their scavenger receptors such as the type A scavenger receptor (SRA), CD36
a member of the type B scavenger receptor, and CD68 [17-19]. Scavenger receptors are mediated
by inflammatory cytokines TNF-α and IFN-γ [46]. Oxidized LDL contains both esterified
cholesterol, which is hydrolyzed in the lysosomes, and free cholesterol, which can undergo
esterification by Acetyl-CoA acetyltransferase or stored in lipid droplets within the macrophage.
Storage of cholesterol within the macrophage results in the formation of a macrophage “foam
cell” which is characteristic of fatty streaks along with lipid droplets in the SMC and appearance
of extracellular lipid accumulation [8, 47].
Fatty streaks develop into intermediate lesions characterized by the increased amount of
extracellular lipid. Intermediate lesions progress to atheroma, which is characterized by a giant
core of extracellular lipid, which disturbs the extracellular matrix and arterial structure. Advanced
atherosclerotic lesions (fibroatheroma) develop due to the accumulation of extracellular lipids,
and the migration and proliferation of smooth muscle cells which take up modified lipoprotein
and synthesize extracellular matrix which leads to fibrous cap development, which is increased
collagen and SMC above the lipid core [24]. The fibrous cap develops around the lesion
encompassing the lipid rich core that contains leukocytes and cellular debris [15]. The core
expands due to further lipid accumulation and the necrosis and apoptosis of vascular smooth
muscle cells and macrophages, all factors contributing to the accumulation of cellular debris,
leading to calcification [24]. As the lesions grows and protrudes into the lumen, the fibrous cap
may begin thinning giving it vulnerability to rupture or the formation of a thrombus [15]. In an
elegant study using ApoE-knockout mice, it was shown that the rate of monocyte recruitment is
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more important to plaque growth than macrophage egress, as complementation with adenovirus
rescuing the apoE phenotype resulted in lesion regression by reducing the rate of monocyte entry
into the lesion [7].
The progression of atherosclerotic lesions into the advanced fibroatheroma involves
further migration of smooth muscle cells from the media to the intima and the enlargement of
the necrotic lipid-rich core, loss of extracellular matrix and proteoglycans, and increase of
calcification [15, 21]. The proliferation of SMC was previously thought to be due to a phenotype
change from contractile to synthetic, but recent studies show the presence of multipotent
vascular stem cells that can differentiate into SMCs [48].
Inflammation plays a role in plaque disruption, proinflammatory cytokines such as IFN-γ
inhibit smooth muscle cell production of collagen while stimulating the production of matrix
metalloproteinases, the dual nature of increased vulnerability through the decreased synthesis
and increased breakdown of collagenous matrix results in a less stable lesion more prone to
rupture [49].
Calcification begins to develop early in the atherosclerotic lesion [50]. Interestingly,
calcification is closely associated with lipid rich regions and cholesterol deposits. Mineral deposits
occur in the core of the lesions, often localized to areas of dead cells and extracellular lipids [21].
Calcification of the vasculature is an active process involving mineralization of the necrotic lipid
core, nucleation sites may form due to vesicles forming from apoptotic bodies of macrophages
and SMC or may nucleate directly off cellular debris [51].
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Tissues In Which Calcification Has Been Observed
Calcification occurs in a myriad of tissue types. The most common type of calcification
occurs in bone biogenesis. This process is a highly regulated process requiring cells to secrete a
calcifiable matrix and initiate calcification. Chondrocytes secrete a matrix consisting of collagen,
which is then calcified via the secretion of calcium containing matrix vesicles. These calcium
phosphate containing matrix vesicles bud off of the outer cell membranes of chondrocytes and
osteoblasts in bone, and odontoblasts in teeth and initiate crystal nucleation of bone, cellular
material with deposited calcium phosphate mineral that aligns with the negative charge of the
collagen matrix [52]. The crystal continues to seed growth of the hydroxyapatite mineral as the
bone continues to form [53].
Another type of calcification that has yet to be studied thoroughly is that of leiomyoma.
Leiomyoma is a benign smooth muscle tumor commonly occurring in the uterus, esophagus, and
skin, and represent the most common gynecological tumor in women of reproductive age [54].
As the leiomyoma enlarges over time they can outgrow the blood supply resulting in ischemic
tissue necrosis and dystrophic changes that may cause the deposition of calcium salts such as
calcium phosphates, and carbonates, although the exact chemical composition and mechanism
remain unknown [40, 55]. This current study demonstrates that lipids, specifically the
dicarboxylic acid AzA forms a complex with calcium, this may hint at the potential for lipids and
calcification in other diseases. Future studies on the involvement of lipids in calcified leiomyoma
may be of interest. The idea that dicarboxylic acids may play a role in other calcifying diseases
has precedence in kidney stones. Oxalic acid is the simplest short chain dicarboxylic acid, and is
10

known to form a calcium salt resulting in kidney stones. Kidney stones are composed mainly of
calcium oxalate and calcium phosphate in the form of apatite [56]. Breast cancer tumors have
been shown to display microcalcification [39]. These various tissues where calcification is
observed represent the diversity of types of pathological mineralization.
This current study focused on vascular calcification of the intima of the vessel wall as a
result of atherosclerosis is a consequence of lipid accumulation, oxidation, and inflammatory
processes [16] .

Figure 1 – Graphical Representation of AzA Hypothesis

AzA is generated as a breakdown product of LDL oxidation within the intima. Linoleic acid
peroxidation results in the generation of the aldehyde species ONA that is further oxidized
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generating AzA. AzA can bind and form a mineralized complex with calcium within the lipid rich
domain of the atherosclerotic plaque.

Techniques used to detect calcification and their pitfalls
Current techniques identify calcium involve histological approaches with dyes and
fluorescent tags, radiographic techniques, near-infrared spectroscopic methods, and
quantification through extraction methods. Histological approaches include the use of von Kossa
staining which utilizes silver nitrate and ultraviolet light to stain calcium. Alizarin red staining is a
specific dye that labels calcium deposits. Other staining techniques involve fluorescent stains of
xylenol orange and calcein blue which are useful in visualizing still growing and ossifying cells as
they do not require prior fixation of the sample [57]. Radiographic methods include the use of xray CT in order to physically visualize the calcified mineral. Radiographic methods are the most
useful for clinical use for visualization calcification in patients.
Both of these techniques, however, focus on the calcium component of the complex, and
do not detect what that calcium is bound to. Studies may have overlooked the potential for
another molecule bound to calcium. This led us to propose the hypothesis that AzA, a
degradation product derived from ox-LDL may be involved. AzA’s association with lipid oxidation
and its ability to bind calcium provided a rationale by which it may be present in calcified
atherosclerotic plaques.
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This study has significant implications in cardiovascular diseases; it addresses key
mechanisms of calcium mineralization within lipid rich domains of the intimal atherosclerotic
lesion, and moreover provides an in vivo rationale for the association of calcification with oxidized
lipids and the overall plaque burden. This study may help unravel the paradoxical observation as
to why antioxidant therapy has failed in the clinical setting despite the fact that oxidative stress
is the central driving force behind the initiation and propagation of atherosclerosis. Our
hypothesis proposes a paradigm shift from an incomplete mechanism to one that incorporates
the association of calcium with the lipid rich domain [58]. Our findings suggest that oxidative and
inflammatory processes are intertwined with the process of calcification and the formation of
the molecular players (i.e. e. AzA) involved. This is the first study of its kind to provide this missing
link.
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CHAPTER TWO: EXPERIMENTAL PROCEDURES
Materials and Reagents
Reagents and chemicals were purchased from Sigma (St. Louis, MO). PCR primers and
Trizol reagent were purchased from Invitrogen (Carlsbad, CA). Declassified human
atherosclerotic tissue samples were purchased from Collaborative Human Tissue Network
(CHTN) from Ohio State University. All studies were performed following approval provided by
the Institutional Review Board (IRB) of the University of Central Florida.

Cell Culture
Human Aortic Smooth Muscle Cells (HASMC) were purchased from ATCC and were
cultured in DMEM/F12 supplemented with 10% fetal bovine serum (FBS). Cells were allowed to
grow to confluence, and were detached by incubation with 0.05% trypsin-EDTA for 3 minutes. To
inhibit trypsin activity, double the volume of media containing FBS was added, followed by
centrifugation at 200 x g for 3 minutes, and suspension in media containing FBS. Cells were
cryopreserved in cryovials with a final concentration of 10% DMSO. Vials were then placed in a
freezing container which contained isopropanol, this ensured that a cooling rate 1 °C per minute
was achieved when the container was placed in -80 °C freezer overnight. Cells were then moved
to a cryopreservation system where they were frozen in the gas phase of liquid nitrogen.
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Preparation of HPODE
13-hydroperoxylinoleic acid (13-HPODE- 200 µM) was prepared as described previously
(47). Lipid peroxide generated in the reaction system was analyzed by LMB assay (4), and the
amount of peroxide generated was quantitated. The oxidized fatty acid was extracted with BHT
free ether, dried under the stream of nitrogen, and stored at −20°C.
Similarly 200 μM radioactive

14C-HPODE

1000 DPM/nmol, was prepared and used for the

experiments.

Synthesis of 9-Oxononanoic Acid
9-Oxononanoic acid was prepared from oleic acid via erythro-9,10- dihydroxysteric acid
(DHSA) (26, 30). Briefly, oleic acid was oxidized to dihydroxystearic acid using potassium
permanganate and was oxidized further by sodium periodate to 9-ONA. After the reaction was
completed, centrifugation was performed at 400g for 5min at 4°C to obtain cellular supernatant.
Supernatant was dried under the stream of nitrogen and purified by TLC using a solvent system
of chloroform, tetrahydrofuran and acetic acid (30/3.3/0.1/6) and confirmed by 2,4Dinitrophenylhydrazine (DNP) staining. Quality of the ONA was further confirmed by LC-MS
analysis. For cell culture studies ONA was suspended in chloroform, dried under the stream of
nitrogen and reconstituted with ethanol, further diluted with PBA and used as needed. Similarly
radioactive ONA (1000 DPM/nmol) was synthesized from 14C-oleicacid and used for the
experiments. Standard AzA on TLC was confirmed by bromocresol green staining.
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Treatment of cells with HPODE/ONA
HASMC were seeded at an initial density of 2 ×104. After attaining confluence, cells were
starved in serum free medium for 3 hours prior to the treatments. Cells were treated with 100
nmoles HPODE and 100 nmoles of ONA for 4 hours in HBSS in presence and absence of 50 µM αtocopherol. After 4 hours of incubation intra- and extra-cellular levels of decomposition products
were analyzed by LC-MS.

LC-MS analysis for in vitro cell culture experiments
Samples were analyzed by LC-MS as described in methodology section. Samples were
extracted from cell lysate by 1 mL of methanol, pipetted well up and down about 5 times. The
sample was centrifuged at 12000 rpm for 15 minute. supernatant was collected and 5 µL of
sample was injected for LC-MS analysis.

Thin layer chromatography and autoradiography 14C-HPODE / 14C-ONA
After treatment of cells with HPODE and ONA in presence and absence of Vitamin E the
cell culture medium and cellular lipid extracts were dissolved in 20 μl of chloroform and loaded
on Silica Gel G TLC plate (Sigma, St. Louis, MO) with standards. Chloroform : Tetrahydrofuran :
Acetic acid (90 : 10 : 0.5) was used as solvent system. After the separation, the TLC plate was left
in the chemical hood for 10 minutes to let solvents evaporate. The dried TLC plate was covered
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with saran wrap and exposed to storage Phosphor screen (Perkin Elmer, MultiSensitive Storage
Screen) for up to 48 hours. Autoradiography was performed using the Cyclone Plus Perkin Elmer
Storage Phosphor System.

Micelle preparation
Azelaic acid (final concentration 100 μmole/L) was mixed with Lyso-PtdCho (final
concentration 50 μmoles/L), vortexed vigorously, and dried under a nitrogen stream. The dried
mixture was resuspended in 10 mL of aqueous media, generating Lyso-PtdCho/AzA micelles
which were used for cell treatment every other day. 10mM β-glycerophosphate was used as a
positive control.

WST-1 Cell Viability Assay
The effect of the Lyso-PtdCho and mixed micelles on cell viability was determined by WST1 assay (Roche Applied Science, IN). HASMC cells (2.5x103 cells/100 µL) were seeded in a 96-well
plate and incubated overnight at 37°C in the presence of 5% CO2. Medium was replaced with
fresh medium containing 50 µmoles/L Lyso-PtdCho, 50 µmoles/L/100 µmoles/L Lyso-PtdCho/AzA
micelles. After incubation, 10 µL of WST-1 reagent, was added to each well in 100 µL of cell
culture medium. Cells were further incubated for 4h at 37°C. Cell viability was determined by
measuring absorbance at 450 nm (630 nm was used as reference wavelength) using a 96-well
plate reader (Benchmark Plus Microplate Spectrophotometer System, Bio-Rad, Hercules, CA).
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Induction of calcification in HASMCs by AzA
HASMCs were grown in standard growth medium supplemented with either Lyso-PtdCho
(50 µmoles/L) alone, or with 50 µmoles/L/100 µmoles/L Lyso-PtdCho/AzA micelles, or with
sodium azelate (100 µmoles/L) for 9 days. Calcification was detected by staining with Alizarin Red
S and von Kossa staining.

Alizarin Red S Staining
After micelle treatment, cells were washed with PBS twice, followed by two washes with
deionized water, then stained with freshly prepared and filtered 2% Alizarin Red S (pH 4.2)
reagent for 1 minute with gentle shaking. Alizarin Red S reagent was aspirated and cells were
washed at least twice with deionized water, followed by PBS, and imaged using the light
microscope with the Leica DFC295 camera (Leica Camera AG, Solms, Germany). Calcium deposits
were visualized by their red color.

von Kossa staining
After micelle treatment, cells were washed four times with PBS and fixed in 10% formalin
for 30 minutes on ice. Formalin was aspirated and cells were washed three times with PBS,
followed by four washes with deionized water, and then incubated with 1% silver nitrate for 4
hours (2 hours under an ultraviolet light followed by 2 hours under a bright fluorescent light).
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Following staining, silver nitrate solution was aspirated and the cells were washed with deionized
water once. To remove background and nonspecific deposits, cells were incubated with 5%
sodium thiosulfate solution for 2 minutes, followed by washing twice with deionized water. Slides
were mounted and imaged using the light microscope Leica DFC295 camera (Leica Camera AG,
Solms, Germany). Calcium deposits are visualized as dark brown to black spots.

Animals
ApoE-PON1 double knockout (DKO) mice were developed using PON1 (-/-) and ApoE (-/-)
mice of C57BL/6J background acquired from Jackson Laboratories (Bar Harbor, ME). Double
knockouts were developed by crossing ApoE(-/-) mice with PON1(-/-) mice for 12 generations.
The mice were genotyped by polymerase chain reaction (PCR) analysis of tail tip DNA, isolated
according to the manufacturer’s instructions using the Dneasy blood and tissue DNA kit (Qiagen,
Germantown, MD) followed by agarose gel electrophoresis. Specific primer sequences from
Jackson Laboratory were used for synthesis and analysis of knockouts.
For our experiments, twenty 2-year old wild type mice weighing 30-35 g and 10 younger
4-month old mice weighing 18-22 g male were used in addition to the ApoE-PON1 DKO mice. The
animals were regularly monitored and a weekly record of body weight was maintained until used
for experiments. All procedures were performed according to protocol approved by The
Institutional Animal Care and Use Committee.
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Collection of Mouse Plasma and Organs
After 2 years of age, mice were fasted overnight and anesthetized with 1-2% isoflurane.
Fasting blood samples were collected into EDTA tubes by heart puncture. Plasma was separated
as described previously (36) and stored at -80°C.

Isolation and Quantification of Mice Aortic Lesions
Isolation of the aorta and quantification of aortic lesions was performed as described
previously (5, 8, 9). Lesion areas were marked on photographs. The lesion area was quantified
using ImageJ software (2). Calcified lesions in aortas were analyzed by x-ray using the Xtreme
imaging system. For histological analysis aortic roots were frozen immediately after imaging,
cryosectioned, fixed, and used for Alizarin Red S staining and von Kossa staining to determine the
presence of calcium, as mentioned previously. All stained sections were observed under light
microscope using Leica DFC295 camera (Leica Camera AG, Solms, Germany).

X-Ray Analysis
Human and mouse aortic tissue samples were separated into calcified and non-calcified
domains using the Bruker in vivo Xtreme imaging system (Billerica, MA) and analyzed using the
Bruker Molecular Imaging Software. X-ray analysis was conducted using an exposure time of 1.20
seconds.
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Isolation Calcified And Non-Calcified Regions of The Human Aortic Tissues
Following IRB approval control and Human calcified tissue samples were collected from
Collaborative human tissue network (CHTN). 9-11 pairs of samples were used for the current
study. The same tissue provided un-involved control, non-calcified, and calcified samples. Age,
gender, pathology and disease severities of subjects are mentioned in supplementary table 1.
Calcified tissues were imaged by using the Xtreme imaging machine. Non calcified and calcified
tissues were separated and confirmed by X-ray analysis. 100mg of sample was used for RNA
isolation.

Micro CT Analysis
To study the differences in the calcified and non-calcified human atherosclerotic plaques
μCT analysis was performed by using the Quantum FX μCT scanner (PerkinElmer, Waltham, MA)
with the following settings: isotropic voxel size of 10 μm, 70 kV, 160 mA, 5 mm field of view, 3
minute scan (FINE setting) per sample. Raw μCT images were processed using Quantum FX μCT
software (PerkinElmer). For the analysis of calcified tissue, the volume enclosing the entire 6-cm
aorta segment is selected. Images were segmented into calcified and non-calcified tissue on each
volume of interest using a global threshold method. After calibration and identification of
calcified tissue, the amount of calcium in the sample were quantified using the Quantum FX μCT
Software.
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Initial Protocol for Aortic Tissue Sample Preparation for LC-MS Analysis
This was the first protocol for extraction of lipids in a calcium complex. Frozen tissue
samples were thawed and each 100 mg of tissue was taken for analysis. Tissue samples were
homogenized in presence of sterile sand thoroughly with mortar and pestle by adding highly
purified sand of about 150 mg. The extraction of analytes from tissue homogenates involved first
a modified Bligh and Dyer method of lipid extraction methanol: chloroform : water (3 mL : 3 mL
: 2.7 mL) and mixed well for 2 minutes by vortex mixer, centrifuged at 2500 rpm for 20 minutes.
The top aqueous layer and bottom organic phases were separated and collected. The
precipitation in the middle layer contained protein and other insoluble material contained the
calcified material. The precipitation was incubated in 2.7 mL of 4N HCl for 2 hours at 50 °C for
dissociation of calcium salts, releasing any associated lipids from calcified domains. The lipids
were extracted by adding methanol : chloroform (3 mL : 3 mL), vortexed for 2 minutes and
centrifuged at 2500 rpm for 20 minutes. The aqueous layer was collected for analysis of calcium
and phosphate (colorimetric kits, Abcam), and the bottom organic phase was analyzed for
organic acids and lipids by LC-MS.

Revised Protocol for Aortic Tissue Sample Preparation for LC-MS Analysis
This method proved to be the optimal method for sample preparation. Tissue (300 mg for
human and 50 mg for mice) was weighed and lyophilized to complete dryness. Dried tissue
samples of human (50 mg) and mice (10 mg) were taken for analysis. The sample extraction
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procedure involved two steps. First, lipids and material not associated with calcium domain were
removed as follows: tissue samples were homogenized and extracted sequentially, with 6 mL of
chloroform and then 6 mL of methanol. Samples were vortexed well and centrifuged at 2500 rpm
for 20 minutes. The supernatants were removed. Second, for extraction of organic acids
associated with calcium, the precipitation was incubated in methanol (6 mL × 2) containing 10%
acetic acid (HAc) at 45°C for 45 minutes, vortexed well, centrifuged at 2500 rpm and the
supernatants were collected. Two extracts were combined and evaporated to dryness under the
gentle stream of nitrogen. The residues were dissolved in 500 µL of methanol containing 0.1%
formic acid. The samples were centrifuged at 12000 rpm for 20 minutes and filtered through 0.22
µm PVDF syringe filters (Fisher Scientific, # 0992728A) for LC-MS/MS analysis. For calcium and
phosphate detection, samples were incubated in water containing 10% HAc at 50°C for 1 hour,
after the removal of lipids and materials that are not associated with calcium.

LC-MS Analysis
Samples were analyzed on Agilent 1200 series high performance liquid chromatography
(HPLC) (Agilent Technologies, CA, USA). The HPLC system consisted of G1379B degasser, G1311A
quaternary pump, HTC PAL autosampler and G1316A column compartment coupled to 6520B
hybrid quadrupole time-of-flight mass spectrometer (QTOF-MS) equipped with dual electrospray
ionization (ESI) source. Analytes were separated on PerkinElmer Brownlee SPP C18 (100 × 2.1
mm, L×ID, 2.7 µm PS, #N9308404) UHPLC column protected with C18 (5×2.1 mm, L×ID, 2.7 µm
PS, # N9308513) guard column. Binary mobile phase gradient program was used to separate the
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molecules, pump-A: methanol and pump-B: water, both containing 0.1% (v/v) formic acid. The
linear gradient program was as follows: 0–8 minutes, 90% B; 8–25 minutes, 10% B; 25–38
minutes, 10% B; 38-38.1; 90% B; 38.1–45 minutes 90% B. The column was operated at 45°C with
a constant mobile phase flow rate of 0.3 mL/minute.
Data were acquired in ESI negative mode for identification of organic acids associated
with calcified domains. Mass spectral data were collected in the mass range of 20–1700 m/z, in
auto MS/MS mode to obtain MS and MS/MS data simultaneously. The mass spectrometer was
tuned at 4GHz high resolution mode at low 1700 m/z range with a manufacturer ESI-TOF
calibration solution (Agilent, #G1969-85000). To ensure good mass accuracy TOF reference mass
solution (Agilent, #G1969-85001) was continuously introduced via the second nebulizer
throughout the analysis. ESI source parameters were optimized and operated under the
following conditions: capillary voltage: 3.5 kV; source temperature: 320°C; nitrogen (N2) used as
a drying and nebulizer gas: 12 L/minutes and 50 psig respectively, TOF parameters: Fragmentor
and skimmer voltages: 100 V and 65 V respectively. N2 used as a CID gas for MS/MS studies,
optimized collision energy (CE) set at 22 volts. The MS data were collected and processed using
Masshunter Qualitative Analysis Software Version B.07.00.
The presence of AzA was confirmed by its high resolution mass detected as deprotonated
molecular ion at m/z 187.0987 eluted at 16.95 (± 0.2). Also confirmed further by analyzing
authentic reference standard of AzA and MS/MS fragmentation spectral match with the
reference standard.
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Quantification of AzA
The developed LC-MS method was validated according to the FDA guidelines
(Bioanalytical method validation, guidance for Industry) for quantitative analysis of AzA in three
types of tissue samples (normal, diseased non-calcified and calcified tissues). Limit of detection
(LOD) and limit of quantifications (LOQ) were calculated in terms of signal to noise ratio (LOD,
S/N≥3 and LOQ, S/N≥ 10), were found to be 50 and 75 pmoles respectively. The linearity of AzA
is examined in matrix spiked and in neat solvent spiked samples at the concentration range of 75
to 5000 pmoles, using stable labeled isotope AzA-D14 as an internal standard (IS) at a constant
concentration of 250 pmoles. The calibration curves were graphed between the area under the
curve ratio of AzA/AzA-D14 against the concentration of AzA. The matrix spiked and neat solvent
calibration curves of AzA shown to be linear, with regression coefficients (R2) greater than 0.995.
Quality control sample were analyzed in triplicates (n=3) at three different concentrations 75,
150 and 300 pmoles to evaluate precision of the method in terms relative standard deviations (%
RSD), observed to be below 13%.

Matrix Effect of Tissue Samples
Matrix effect (ME, %) of the method was determined by comparing response ratio of
analyte and IS (AzA/AzA-D14, AUC) in standard solution against with the matrix spiked standards
(30). ME was calculated at three different concentration levels, 75 (LOQ), 150 and 300 pmoles,
in triplicates (n=3) and found to be 10.13, 8.63 and 5.6 % respectively.
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Extraction Recovery Of AzA From Tissues Samples
Extraction recovery (ER, %) of AzA was calculated by pre extraction and post extraction
spikes of calcium-azelate (Ca-AzA). Blank matrix ensured that AzA was absent in tissue
extract/diluted matrix for matrix spiking experiments. Pre extraction spike: Ca-AzA added to the
tissue samples and stored at -80°C overnight, thawed the next day, homogenized and extracted
as described in sample preparation section. post extraction spike: Ca-AzA was added to the
acidified methanol tissue extract and incubated at 45°C for 30 minutes. ER carried out at three
different concentrations, 75 (LOQ), 150 and 300 pmoles in triplicates (n=3) and found to be 71.7,
76.7 and 81.2 % respectively.

Calcium and Phosphate Quantification
Samples were prepared as described in methods; calcium and phosphate were quantified
using Abcam (Cambridge, MA) colorimetric assay kits, calcium colorimetric assay (ab102505) and
phosphate colorimetric assay (ab65622) following the instructions of supplier’s protocol.

Alkaline Phosphatase Activity Assay
Alkaline phosphatase activity was measured on freshly homogenized human aortic tissue
(100mg) incubated with 14 µL substrate (water with para-nitrophenol at 100 millimoles/L,
sodium bicarbonate at 1.43 moles/L, and magnesium chloride at 71.4 millimoles/L), and brought
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up to 200 μL. Samples were incubated at 37°C for 30 minutes and read at 410 nm on a plate
reader (Benchmark Plus Microplate Spectrophotometer System, Bio Rad, Hercules, CA).

Statistical Analysis
Values are presented as a mean ± standard deviation (SD), and statistical analyses were
performed by using a student’s t-test, with P<0.05 as the acceptable level of significance. For
multiple group comparisons, one way ANOVA-Bonferroni multiple comparison test was used with
p<0.05 as the level of significance.
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Abstract
Aim: In this study, we tested the hypothesis that lipid peroxide-derived dicarboxylic acids, by
virtue of their ability bind to calcium, might be involved in atherosclerotic calcification. We
determined the ability of azelaic acid (AzA) to promote calcification in human aortic smooth
muscle cells (HASMC), identified AzA in human calcified atherosclerotic lesions, and compared
its levels with control and non-calcified atherosclerotic lesions.
Results: HASMCs efficiently converted 9-oxononanoic acid (ONA), a lipid peroxide derived
monocarboxylic aldehyde, to AzA. In vitro incubations of AzA micelles with HASMC resulted in
the formation of calcium deposits which contained AzA. LC-MS analysis of human control
uninvolved artery, non-calcified, and calcified lesions showed significant increase of AzA in
calcified lesions compared to non-calcified and control tissues. Calcified mouse atherosclerotic
lesions also showed substantial presence of AzA in calcium complexes.
Innovation: This study identifies a dicarboxylic acid, AzA, as an integral part of the calcium
complex. The study also demonstrates the conversion of a lipid peroxidation product, ONA as a
potential source of AzA, and establishes the presence of AzA in calcified materials isolated from
human and mouse lesions.
Conclusion: The presence of AzA as a calcium sequestering agent in atherosclerotic lesions might
indicate, a) participation of oxidized-LDL (Ox-LDL) derived products in calcification, b) explain the
potential correlation between calcification and overall plaque burden (as Ox-LDL has been
suggested to be involved in atherogenesis), c) could contribute to plaque stabilization via its anti-
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inflammatory actions, and d) might explain why antioxidants failed to affect atherosclerosis in
clinical studies.
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Introduction
It is currently believed that atherosclerosis progresses as early fatty streak lesions
progress to raised complex lesions, involving smooth muscle cell proliferation, which may
eventually become calcified [15, 59, 60]. Calcification is a major independent predictor of
cardiovascular morbidity and mortality [23, 61]. Smooth muscle cells express bone differentiation
markers such as alkaline phosphatase, which is suggested to provide phosphate for the formation
of calcium phosphate [62]. Accordingly, it is widely believed that calcium (Ca) in lesions might be
present as calcium phosphate. Calcification is mainly identified by staining techniques such as
von Kossa or alizarin red S staining, or by physical imaging techniques such as computerized
tomography scan (CT-Scan) [63-66]. While these techniques detect mineralized calcium, they do
not indicate the chemical form in which calcium is deposited.
During the past three decades, the concept of oxidized low density lipoprotein (Ox-LDL)
has emerged as a key player in the development of atherosclerosis. Overwhelming in vitro and in
vivo evidence support the hypothesis [1, 67, 68]. The failure of human antioxidant trials,
however, raised concerns about the validity of the hypothesis, at least in humans. Numerous
review articles have appeared on the topic, including the suggestion that oxidative stress might
be beneficial under certain circumstances [25, 69-71].
The breakdown of peroxidized lipids into aldehydes, both free and core aldehydes, have
been well documented [72-74]. Linoleic acid is the major polyunsaturated fatty acid (PUFA) of
LDL, and the oxidation of linoleic acid generates toxic and reactive aldehydes (e.g. 4-hydroxy
nonenal (4-HNE) and 9-oxononanoic acid (ONA)), which have been shown to be highly pro31

inflammatory [75-78]. However, aldehydes are also extremely oxidation-labile and are readily
converted into carboxylic acids by a variety of enzymatic and non-enzymatic processes [79, 80].
The Ox-LDL particle is also associated with the increased presence of Lyso-phosphatidylcholine
(Lyso-PtdCho) that could carry aldehydes and their oxidation products into cells [81, 82].
While 4-HNE has been well studied, aldehydes generated from the carboxylic acid end of
fatty acid oxidation products, for example ONA, have not been studied as extensively. Its
oxidation product, azelaic acid is a poorly studied dicarboxylic acid (DCA). We recently reported
that animals fed AzA had decreased atherosclerotic lesions as compared to control
atherosclerotic mice [25].
Calcium phosphate as the sole calcified material does not explain the association of
calcification with lipid-rich domains nor the latter’s intra- and extra- cellular presence or its
correlation with overall plaque burden [23]. In this study, we considered the possibility that AzA
or other DCAs, derived from lipid peroxide-derived aldehydes, by virtue of their ability to bind
calcium might explain the relationship of calcification to the etiology (Ox-LDL) of atherosclerosis
and the association with lipid accumulation. As a medium chain DCA, it would also bind calcium
with higher affinity as compared to monocarboxylic acids [83, 84], and sequester calcium in lipidrich domains. In addition, AzA has been noted to have anti-inflammatory properties and has been
noted to decrease cytokine production by macrophages and inflammatory cells [85, 86]. It also
has been demonstrated to reduce oxidant production by leukocytes [87]. Thus, AzA as a calcium
binding lipid would explain the association of calcium with the lipid rich plaque and the
association of calcification with products derived from Ox-LDL, and would account for the
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correlation of calcification with the overall plaque burden. This study is the first to suggest a direct
link between DCA products derived from oxidation of aldehydes and calcification.
Using in vitro cultured human aortic smooth muscle cells (HASMC), we demonstrate the
ability of ONA to get oxidized to AzA, and the ability of the latter to promote calcification in
smooth muscle cells. We also unequivocally demonstrate the increased presence of AzA in
calcified domains of atherosclerotic lesions by liquid chromatography-mass spectrometry (LCMS) analysis, using both in vitro and in vivo (human and mice) samples.

Results
Decomposition of lipid peroxides by HASMCs
Lipid peroxides and their aldehyde breakdown products play major roles in the
progression of atherosclerosis. To demonstrate an active role of HASMCs in the decomposition
of lipid peroxides into aldehydes and to oxidize the latter into carboxylic acid, HASMCs were
incubated with 100 µM 13-hydroperoxyoctadecadienoic acid (HPODE), and increased AzA levels
were observed by LC-MS analysis (Fig 1A). HPODE (Supplementary Fig.1) degradation was also
monitored by the loss of leukomethylene blue (LMB) reactivity and the decrease in optical density
at 234 nm (loss of conjugated dienes). As seen in the figure, the peroxides were lost in less than
2 hours in the presence of cells as compared to no cell incubations.
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Figure 2 – HASMC Decomposition of HPODE and Conversion of ONA to AzA is Inhibited by α-Tocopherol

HASMC induced decomposition of HPODE and Conversion of ONA to AzA is inhibited by
α-Tocopherol. HASMCs were grown to confluence and incubated with A) HPODE and B) ONA in
the presence and absence of α-tocopherol for 6 hours. After treatment, AzA was quantified by
LC-MS analysis.

In addition,

14C-HPODE

was prepared and used further to confirm the HPODE

decomposition in presence of HASMC for 6hours in HBSS. Autoradiography data indicated that
HPODE was converted to AzA in the medium in presence of cells as compare to a no cell control,
respectively (Supplementary Figure 2A).
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Conversion of ONA to AzA in the presence of α-tocopherol and HASMC
Although AzA is present in many food materials in unknown quantities, in the body it is
likely to be generated from fatty acids. Oxidized fatty acids decompose to generate a number of
different short chain (e.g. malondialdehyde, hexanal) to medium chain aldehydes (e.g. 4-HNE,
ONA). Oxidation of these aldehydes, enzymatically or non-enzymatically, is expected to yield
carboxylic acids. The oxidation of ONA is expected to yield AzA. To evaluate whether ONA is
converted to AzA by cells, ONA was prepared and incubated with HASMCs as described in the
methods both in presence and absence of α-tocopherol. As shown in Figure 1B, LC-MS analysis
showed a significant decrease in AzA at 6 hours of incubation with HASMCs in presence of αtocopherol as compared to the absence of α-tocopherol, suggesting that antioxidants inhibit the
conversion of ONA to AzA.
In addition, radioactive

14C-ONA

was also synthesized and used in these experiments.

Autoradiography data showed a significant increase in AzA as shown in the figure (Supplementary
Fig 1B) in the absence of α-tocopherol, whereas there was no or less change in ONA
concentration as compared to control cell incubations at all time intervals.
Loading of HASMC with AzA results in calcification
To assess calcium accumulation upon AzA supplementation, HASMCs were treated with
mixed micelles of Lyso-PtdCho/AzA as indicated in the methods section. At the concentrations
used, little or no cytotoxicity was observed, as determined by microscopy and lactate
dehydrogenase release. Percentage of cell viability was calculated using control untreated cells
as 100% viability. As shown in the Supplementary Fig. 3, Lyso-PtdCho/AzA mixed micelles at the
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concentrations used have no obvious toxic effects on HASMCs, as compared to Lyso-PtdCho
alone. After incubation and washings, the cells were stained with von Kossa stain, which stains
calcium deposits by a dark brown/black silver residue. As seen in Fig. 2 there was minimal staining
of control cells. Minimal staining was seen with Lyso-PtdCho micelles alone. However, cells
treated with the mixed micelles stained significantly darker suggest robust calcification. LC-MS
analysis also confirmed the increased presence of AzA bound to calcium in HASMCs treated with
Lyso-PtdCho/AzA mixed micelles, as shown in Figure 2E. As a positive control for calcification,
HASMCs were treated with β-glycerophosphate, as shown in Supplementary Fig 4.
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Figure 3 – Calcification of HASMC induced by AzA micelle treatment

Cells were grown to confluence and incubated for 9 days under the following conditions:
A. Untreated B. Na-AzA at 100 µmole per liter C. Lyso-PtdCho micelles at 50 μmole per liter D.
Lyso-PtdCho/AzA Micelles at 50 μmole per liter / 100 μmole per liter. Cells were stained for
calcium deposits using von Kossa staining (calcium deposits appear dark brown spots). Image
Magnification 40X. E. AzA quantification in nmoles.
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Detection of AzA in tissues
Calcification involves generation of insoluble complexes. In order to identify whether the
mineralized calcium could contain AzA as a calcium complex, we first removed the non calciumbound lipids by chloroform-methanol extraction, the soluble organic and aqueous phases were
removed. This ensures that any non-calcium complexed AzA has been removed. The remaining
insoluble material that contained protein and mineralized calcium complexes was subjected to
acid hydrolysis with 10% acetic acid in methanol. The acid hydrolyzed material is expected to
have calcium in the form of calcium chloride, and free AzA (no longer complexed with calcium).
This was used to determine calcium and AzA concentrations. The tissue was processed as
described in the methods.
Simply stated this method first involved the removal of the non calcium complexed lipids.
After these non-mineralized lipids were removed, the calcified material was subjected to acid
hydrolysis, which hydrolyzed the complex forming calcium chloride and free AzA. This free AzA
was then extracted and quantified via LC-MS. This ensures any AzA analyzed was bound with
calcium, as any free non-calcium complexed AzA would have been removed in the first lipid
extraction.

Identification of calcification in aged ApoE-PON1 double knockout mice
ApoE-PON1 double knockout (DKO) mice of over 2 years of age on a normal diet were
used, as this DKO mouse model has been shown to have increased atherosclerotic lesions (49).

38

Comparatively, aged wild type mice and younger DKO mice (4 months) were used as controls. A
significant increase in body weight, liver weight and plasma lipids were observed in the aged DKO
mice as compared to controls (Supplementary Fig. 5). These mice also displayed extensive lesions
upon dissection of the aortic arch, as indicated by the regions of white, opaque areas of the vessel
(Fig. 3A). After confirming the presence of calcification by CT scan (Fig. 3B), histological
examination of the aortic arch was performed and also displayed extensive calcification as
determined by von Kossa (Fig. 3C) and alizarin red staining (Fig. 3D). Further, extensive
calcification of the aortic arch and aortic root confirmed by the X-ray imaging (Fig. 3E-F). Figure
3G-I represents the phosphate, calcium, and AzA levels from pooled samples (n=9) in calcified
and non-calcified lesions of mouse aortic samples. The results showed that AzA was found in
significant amounts in calcified tissues as compared to non-calcified region. The lesion area of all
the aortas as compared to control animals is represented in Supplementary Fig. 6.
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Figure 4 – Calcification in aged ApoE-PON1 double knockout mice

A. Photograph of dissected aortic loop. B. microCT scan of dissected aortic loop C. Calcium
stain of aortic loop cross sections (image magnification 10x) stained with B. von Kossa stain and
D. Alizarin Red S stain. E. Images of dissected mouse aorta. F. X-ray scan image of dissected mouse
aorta. G. Calcium quantification of mouse lesion calcified domains. H. Phosphate quantification
of mouse lesion calcified domains. I. Fold increase in LC-MS signal for AzA in mouse calcified
domains. Mean ± SEM, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, (t-test).
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Identification of calcification in human atherosclerotic aortic plaques
To identify the presence of AzA in calcified human atherosclerotic plaques we first needed
to determine the presence of calcification in these human aortic samples by X-ray imaging (Fig.
4). Tissues were dissected to obtain non-lesion normal tissue, non-calcified atherosclerotic tissue,
and calcified atherosclerotic lesions. Calcified domains were dissected from the non-calcified
atherosclerotic plaques and re-imaged to verify dissection (Fig. 4A). Control tissue was also
analyzed to confirm no calcification was present in the non-diseased tissue. The non-diseased
and diseased pairs of aortic lesion tissue were acquired from the same individual, pathological
reports of the tissues analyzed is shown in (Supplementary table 1). The tissues were used for
the analysis of calcium, phosphate, and AzA levels. Fig. 4B–E represents the calcium, phosphate,
and AzA levels in normal tissue, calcified lesions, and non-calcified lesions of human aortic
samples. Quantification of calcium, phosphate, and AzA of individual samples were represented
in Supplementary Table 2. MicroCT X-ray analysis of samples is also represented in the Fig. 5. As
seen in the figure, presence of calcium was increased in calcified lesions as compared to other
two controls. This confirmed the calcified lesions did indeed contain calcified deposits while the
normal and non-calcified tissues were not calcified.
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Figure 5 – Calcification in human aortic tissue samples

A. X-ray images showing calcified regions as dark regions. B. Calcium quantification of
calcium deposit associated calcium. C. Phosphate quantification in nmoles of calcium deposit
associated phosphate. D. AzA quantification in nmoles of calcium deposit associated AzA. Mean
± SEM, n=9, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (One way ANOVA Bonferroni multiple
comparison test).
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Figure 6 – Human aortic tissue microCT images.

A. Representative cross sections of microCT images for human aortic tissue samples. B.
Densitometry of calcified domains. Mean ± SEM, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001(t-test).

AzA quantification in tissue samples
Human and mouse tissues were analyzed in a validated LC-MS method for quantitative
analysis of AzA using AzA-D14 as an internal standard. The detected AzA presented in
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Supplementary Table 2 shows quantified AzA in nmoles. The representative LC-ESI-HRMS
extracted ion chromatograms - AzA ([M-H]-187.0976) and AzA-D14 (IS, ([M-H]- 201.1849)), ESIMS and MS/MS spectra and proposed fragment ions shown in Fig. 6.

Figure 7 – The representative LC-ESI-HRMS extracted ion chromatograms.

AzA ([M-H]-187.0976) and AzA-D14 (IS, ([M-H]- 201.1849)) (A), ESI-MS and MS/MS
spectra (B) and proposed fragment ions (C).

Increased presence of calcium and AzA in calcified human atherosclerotic lesions Calcium
was identified in the control, non-calcified, and calcified lesions. As seen in Fig. 4, there was a
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several fold and significant increase in calcium in the calcified lesions, confirming the dissection
and analytical techniques employed. The presence of AzA was established by LC/MS and we
detected a significant increase in AzA concentrations in the calcified tissue as compared to the
other two controls (Fig. 4). Although our focus was on AzA, oxidation of PUFA is expected to
generate a plethora of DCAs, including a 12-carbon acid. We indeed observed several other minor
mass ions in the isolated calcium complex, but have not established their chemical identities.
The amount of AzA, even if other DCAs (and even mono carboxylic acids) were present,
did not fully match the levels of calcium. Combined with the unknown stoichiometry of the
carboxylic acids with calcium, we kept in mind the possibility of the presence of free phosphates
in the analysis. As seen in Fig. 4, although phosphates were present in significantly higher
amounts in the calcium complex than azelate, the results of our study suggest that in addition to
calcium phosphates, calcium azelate also contribute to atherosclerotic calcification.
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Supplementary Figures

Figure 8 – Decomposition of HPODE by HASMC.

HASMC were incubated with 100 μ M HPODE. Decomposition of peroxides were
determined by LMB assay over time both in the presence and absence of cells. Mean ± SEM, n=3;
* p ≤ 0.05, ** p ≤ 0.01 (t-test).
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Figure 9 – Thin Layer Chromatography autoradiograph of the lipid fractions.

A. HPODE decomposition products, both in presence and absence of HASMC cells in
medium over time, and B. Conversion of ONA to AzA by HASMC in presence and absence of
(Vitamin E) α-tocopherol. Representative images of three independent experiments.
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Figure 10 – The effect of micelle treatment on HASMC cell viability.

HASMC were exposed to Lyso-PtdCho micelles at concentration 50 μmole per liter and
Lyso-PtdCho/AzA at 50 μmole per liter / 100 μmole per liter, and the WST-1 assay was performed
following the instructions of supplier’s protocol. Viable cells metabolize WST-1 reagent increasing
the absorbance at 450 nm. Mean ± SEM, n=3; Untreated vs. Treated, * p ≤ 0.05, ** p ≤ 0.01 (ttest).
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Figure 11 – HASMC Calcification Positive Control

Cells were grown to confluence and incubated for 9 days with standard medium
supplemented with 10mM β-glycerophosphate. Cells were stained for calcium deposits using von
Kossa staining method (calcium deposits appear dark brown spots). Image was captured at 40X
magnification.
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Figure 12 – ApoE-Pon1 DKO Plasma Lipids Profile.

Young (4 month) and aged (≥2 year) DKO mice were compared with control mice. A.
Average weight of mice in grams. B. Average liver weight of mice in grams. C. Lipid profile of mice
(in mg/DL) of triglycerides, total cholesterol, high density lipoprotein, low density lipoprotein,
and very low density lipoprotein. D. Ratio of Total Cholesterol to HDL. Mean ± SEM; Untreated
vs. Treated, * p ≤ 0.05, ** p ≤ 0.01, (t-test).
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Figure 13 – Lesion area of ApoE-Pon1 DKO mice.

A. Photographs of lesion areas in dissected aortic loops. B. Quantified lesion area of mice
in mm2. Mean ± SEM;, *** p ≤ 0.001..
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Figure 14 – Human Aortic Tissue Samples Clinical Diagnosis of Subjects.

Supplementary Table 1 Human Aortic Tissue Samples Clinical Diagnosis of Subjects.
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Figure 15 – Human Aortic Tissue Samples Quantified Molecules in nmoles.

Supplementary Figure 2. Human Aortic Tissue Samples Quantified Molecules in nmoles.
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Discussion
In this study, we present a new paradigm that atherosclerotic calcification may also
involve calcium binding DCA products derived from Ox-LDL.
Calcium deposits are found more frequently and in greater amounts in elderly patients with
atherosclerosis with more advanced lesions [88, 89]. The extent of calcification has been
correlated with plaque burden, suggesting that factors that contribute to atherosclerosis
development may have a direct relationship with calcification.
The role of Ox-LDL and the effects of lipid peroxides and their aldehyde breakdown products on
atherosclerosis have been studied extensively [90, 91]. Aldehydes are chemically unstable
intermediates and are readily oxidized to carboxylic acids, In addition to spontaneous oxidation,
a variety of enzymes and processes are capable of converting aldehydes into carboxylic acids. In
some cases (i.e. xanthine/aldehyde oxidases), the process itself generates free radicals [86, 92].
We recently reported the oxidation of aldehydes by the myeloperoxidase (MPO) / HOCl system
[26]. Of particular interest to us is aldehyde oxidase 1 (AOX1), which has been reported as an ATP
binding cassette transporter-A1 (ABCA1)-interacting protein [93]. Most carboxylic acids derived
from the oxidation of aldehydes formed via the decomposition of lipid peroxides are simple, short
chain molecules from the ω-end. These are very rapidly metabolized by simple β-oxidation
pathways and are rarely used as an anabolic intermediate. The DCA could be from the middle of
the molecule (e.g. malondialdehyde) or mostly from the carboxyl end (e.g. AzA). Obviously some
type of esterase/PLA2 is needed to release the carboxyl moiety.
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In this study, we demonstrate that AzA may play a role in calcification. AzA is used
extensively as an anti-inflammatory and antioxidant agent [94], but has not been implicated in
atherosclerotic calcification. AzA has the ability to bind calcium forming a complex, and our in
vitro studies have shown its ability to induce calcification of HASMC upon intracellular micelle
delivery. In order to understand its involvement in vivo, we extracted calcified material from
atherosclerotic plaques and were able to identify AzA upon acid hydrolysis of the insoluble
calcified deposits. The LC-MS identification of AzA, both in mice and human lesions, in isolated
mineralized calcium deposits, conclusively demonstrates that AzA was an integral part of the
calcium deposits. Free AzA would have been removed by extraction with the organic solvent
during lipid extraction and any soluble Ca salts would have been partitioned into the aqueous
phase. Thus, the presence of both Ca and AzA in the insoluble material and their release only
upon acid hydrolysis suggest that they are present together. This is the first study to detect
medium chain DCA in the calcium deposits of human atherosclerotic lesions.
Ox-LDL is intimately involved in atherosclerotic progression, as it is internalized by
macrophages during the formation of early atherosclerotic fatty streak lesions. Ox-LDL also plays
a role in subsequent development of advanced lesions by promoting SMC migration and affecting
plaque vulnerability. Thus, the presence of oxidized lipids, and products derived from oxidized
lipids, would be expected to correlate with the overall plaque burden. As the current study
implicates DCAs, including AzA in calcification, it would be no surprise that the extent of
calcification is a representation of the overall plaque burden. Moreover, oxidized medium chain
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DCAs such as AzA are lipophilic, derived from lipids, and thus are expected to be present in the
lipid rich domain of the lesion, where they may bind to calcium and form insoluble complexes.
There has been a great deal of debate about the role of calcification in plaque rupture
[42, 95-97]. Calcification has been noted as both intra- and extra- cellular deposits [98], the latter
predominantly is associated with extracellular lipids. Many researchers believe that coronary
arterial calcification may represent an attempt to protect the weakened atherosclerotic plaque
prone to rupture [42, 99]. Calcified lesions and fibrotic lesions are much stiffer than cellular
lesions and are unlikely to be associated with sites of plaque rupture [42, 99]. In fact, a recent
study showed that less than 15% of the ruptured human lesions showed evidence of associated
calcification (58). It is speculated that the plaque rupture often occurs at the interface between
a calcified and non-calcified atherosclerotic area of the lesion. Thus, calcification could be seen
as a potential stabilizing force that may increase the biochemical stability of the plaque by
imparting rigidity while at the same time decreasing the plaque’s mechanical stability. While the
presence of calcium phosphate is not ruled out in this study, the finding that AzA, an antiinflammatory molecule, is associated with calcium could suggest it imparts other potential effects
to the calcified domain besides affecting the stability of calcified plaques.
Our findings are of great interest and could explain the failure of antioxidant trials in
treating human atherosclerosis. Antioxidants inhibit a variety of oxidative processes, including
many enzymatic and non-enzymatic oxidative pathways. We have noted the inhibition of
conversion of ONA to AzA in the presence of antioxidants (Figure 1B). Thus, the formation of DCA
from ONA may represent a protective mechanism to thwart plaque vulnerability. Furthermore,
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antioxidants under such circumstances might result in the accumulation of toxic and proinflammatory aldehydes and promote plaque vulnerability (Figure 7 - Scheme 1). Combined with
our findings (29) that AzA prevented atherosclerosis without affecting lipid levels and decreased
CD68 positive macrophages in the lesions, this study suggests additional benefits in promoting
the oxidation of toxic aldehydes to innocuous carboxylic acids.

Figure 16 – Schematic representation of the AzA hypothesis.

Schematic representation of the hypothesis.
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Innovation
Atherosclerosis has been suggested to involve the oxidation of LDL associated
polyunsaturated fatty acids. Many aldehydes are formed as a result of decomposition of lipid
peroxides. However, their propensity to undergo further oxidation to carboxylic acid has been
vastly ignored. This is the first study to demonstrate the ability of AzA to bind calcium and suggest
that calcium azealate could contribute to atherosclerotic calcification. The presence of AzA in
lesions might suggest why antioxidant trials might have failed to prevent atherosclerosis, as they
would also inhibit the conversion of toxic aldehydes to carboxylic acids.
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Methods
Materials and reagents
Reagents and chemicals were purchased from Sigma (St. Louis, MO). PCR primers and
Trizol reagent were purchased from Invitrogen (Carlsbad, CA). Declassified human
atherosclerotic tissue samples were purchased from Collaborative Human Tissue Network
(CHTN) from Ohio State University. All studies were performed following approval provided by
the Institutional Review Board (IRB) of the University of Central Florida.

Cell culture
Human Aortic Smooth Muscle Cells (purchased from ATCC) were cultured in DMEM/F12
supplemented with 10% fetal bovine serum (FBS).

Preparation of HPODE
13-hydroperoxylinoleic acid (13-HPODE- 200 µM) was prepared as described previously
(47). Lipid peroxide generated in the reaction system was analyzed by LMB assay (4), and the
amount of peroxide generated was quantitated. The oxidized fatty acid was extracted with BHT
free ether, dried under the stream of nitrogen, and stored at −20°C.
Similarly 200 μM radioactive

14C-HPODE

1000 DPM/nmol, was prepared and used for the

experiments.
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Synthesis of 9-Oxononanoic Acid
9-Oxononanoic acid was prepared from oleic acid via erythro-9,10- dihydroxysteric acid
(DHSA) (26, 30). Briefly, oleic acid was oxidized to dihydroxystearic acid using potassium
permanganate and was oxidized further by sodium periodate to 9-ONA. After the reaction was
completed, centrifugation was performed at 400 g for 5min at 4°C to obtain cellular supernatant.
Supernatant was dried under the stream of nitrogen and purified by TLC using a solvent system
of chloroform, tetrahydrofuran and acetic acid (30/3.3/0.1/6) and confirmed by 2,4Dinitrophenylhydrazine (DNP) staining. Quality of the ONA was further confirmed by LC-MS
analysis. For cell culture studies ONA was suspended in chloroform, dried under the stream of
nitrogen and reconstituted with ethanol, further diluted with PBA and used as needed. Similarly
radioactive ONA (1000 DPM/nmol) was synthesized from 14-C oleic acid and used for the
experiments. Standard AzA on TLC was confirmed by bromocresol green staining.

Treatment of cells with HPODE/ONA
HASMC were seeded at an initial density of 2 ×104. After attaining the confluence, cells
were starved in serum free medium for 3 hours prior the treatments. Cells were treated with
100nmoles HPODE and 100nmoles of ONA for 4 hours in HBSS in presence and absence of 50 µM
α-tocopherol. After 4 hours of incubation intra- and extra-cellular levels of decomposition
products were analyzed by LC-MS.
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LC-MS analysis for in vitro cell culture experiments
Samples were analyzed by LC-MS as described in methodology section. Samples were
extracted from cell lysate by 1 mL of methanol, pipetted well up and down about 5 times. The
sample was centrifuged at 12000 rpm for 15 minutes, supernatant was collected and 5 µL of
sample was injected for LC-MS analysis.

Thin layer chromatography and autoradiography 14C-HPODE / 14C-ONA
After treatment of cells with HPODE and ONA in presence and absence of Vitamin E the
cell culture medium and cellular lipid extracts were dissolved in 20 μl of chloroform and loaded
on Silica Gel G TLC plate (Sigma, St. Louis, MO) with standards. Chloroform : Tetrahydrofuran :
Acetic acid (90 : 10 : 0.5) was used as solvent system. After the separation, the TLC plate was left
in the chemical hood for 10 minutes to let solvents evaporate. The dried TLC plate was covered
with saran wrap and exposed to storage Phosphor screen (Perkin Elmer, MultiSensitive Storage
Screen) for up to 48 hours. Autoradiography was performed by Cyclone Plus (Perkin Elmer
Storage Phosphor System).

Micelle preparation
Azelaic acid (final concentration 100 μmole/L) was mixed with Lyso-PtdCho (final
concentration 50 μmoles/L), vortexed vigorously, and dried under a nitrogen stream. The dried
mixture was resuspended in 10 mL of aqueous media, generating Lyso-PtdCho/AzA micelles
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which were used for cell treatment every alternate day. 10mM β-glycerophosphate was used as
a positive control.

WST-1 cell viability assay
The effect of the Lyso-PtdCho and mixed micelles on cell viability was determined by WST1 assay (Roche Applied Science, IN). HASMC cells (2.5x103 cells/100 µL) were seeded in a 96-well
plate and incubated overnight at 37°C in the presence of 5% CO2. Medium was replaced with
fresh medium containing 50 µmoles/L Lyso-PtdCho, 50 µmoles/L/100 µmoles/L Lyso-PtdCho/AzA
micelles. After incubation, 10 µL of WST-1 reagent was added to each well in 100 µL of cell culture
medium. Cells were further incubated for 4h at 37°C. Cell viability was determined by measuring
absorbance at 450 nm (630 nm was used as reference wavelength) using a 96-well plate reader
(Benchmark Plus Microplate Spectrophotometer System, Bio-Rad, Hercules, CA).

Induction of calcification in HASMCs by AzA
HASMCs were grown in standard growth medium supplemented with either Lyso-PtdCho (50
µmoles/L) alone, or with 50 µmoles/L/100 µmoles/L Lyso-PtdCho/AzA micelles, or with sodium
azelate (100 µmoles/L) for 9 days. Calcification was detected by staining with Alizarin Red S and
von Kossa staining.

62

Alizarin Red S staining
Tissue sections were washed with PBS twice, followed by two washes with deionized
water, then stained with freshly prepared and filtered 2% Alizarin Red S (pH 4.2) reagent for 1
minute with gentle agitation. Alizarin Red S reagent was removed followed by two washes with
deionized water and PBS, then imaged using the light microscope with the Leica DFC295 camera
(Leica Camera AG, Solms, Germany). Calcium deposits were visualized by their red color.

von Kossa staining
After micelle treatment, cells were washed four times with PBS and fixed in 10% formalin
for 30 minutes on ice. Formalin was aspirated and cells were washed three times with PBS,
followed by four washes with deionized water, and then incubated with 1% silver nitrate for 4
hours (2 hours under an ultraviolet light followed by 2 hours under a bright fluorescent light).
Following staining, silver nitrate solution was aspirated and the cells were washed with deionized
water once. To remove background and nonspecific deposits, cells were incubated with 5%
sodium thiosulfate solution for 2 minutes, followed by washing twice with deionized water. Slides
were mounted and imaged using the light microscope Leica DFC295 camera (Leica Camera AG,
Solms, Germany). Calcium deposits are visualized as dark brown to black spots. Tissue sections
were similarly stained.
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Animals
ApoE-PON1 double knockout mice were developed using PON1(-/-) and ApoE(-/-) mice of
C57BL/6J background from Jackson Laboratories (Bar Harbor, ME). Double knockouts were
developed by crossing ApoE(-/-) mice with PON1(-/-) mice for 12 generations, as described by (49).
The mice were genotyped by polymerase chain reaction (PCR) analysis of tail tip DNA, isolated
according to the manufacturer’s instructions using the Dneasy Blood and tissue DNA kit (Qiagen,
Germantown, MD) followed by agarose gel electrophoresis. Specific primer sequences from
Jackson Laboratory were used for synthesis and analysis of knockouts.
Twenty 2-year old mice weighing 30-35 g and ten younger 4-month old mice weighing 1822 g male ApoE-PON1 DKO mice were used. Ten 7-month old C57BL6/J male mice were
purchased and maintained. The animals were regularly monitored and a weekly record of body
weight was maintained until used for experiments. All procedures were performed according to
protocol approved by The Institutional Animal Care and Use Committee.

Collection of plasma and organs
After 2 years of age, mice were fasted overnight and anesthetized with 1-2% isoflurane.
Fasting blood samples were collected into EDTA tubes by heart puncture. Plasma was separated
as described previously (39) and stored at -80°C.
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Isolation and quantification of mice aortic lesions
Mice aorta were isolated and photographed for quantification lesion size. The lesion area
was quantified using ImageJ software. Calcified lesions in aortas were analyzed by x-ray using the
Xtreme imaging system. For histological analysis aortic roots were frozen immediately after
imaging, cryosectioned, fixed, and used for Alizarin Red S staining and von Kossa staining to
determine the presence of calcium, as mentioned previously. All stained sections were observed
under light microscope using Leica DFC295 camera (Leica Camera AG, Solms, Germany).

X-Ray analysis
Human and mouse aortic tissue samples were separated into calcified and non-calcified
domains using the Bruker in vivo Xtreme imaging system (Billerica, MA) and analyzed using the
Bruker Molecular Imaging Software. X-ray analysis was conducted using an exposure time of 1.20
seconds.

Isolation calcified and non-calcified regions of the human aortic tissues
Following IRB approval control and Human calcified tissue samples were collected from
Collaborative human tissue network (CHTN). 9-11 pairs of samples were used for the current
study. The same tissue provided un-involved control, non-calcified, and calcified samples. Age,
gender, pathology and disease severities of subjects are mentioned in supplementary table 1.
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Calcified tissues were imaged by using the Xtreme imaging machine. Non calcified and calcified
tissues were separated and confirmed by X-ray analysis.

Micro CT analysis
To study the differences in the calcified and non-calcified human atherosclerotic plaques
μCT analysis was performed by using the Quantum FX μCT scanner (PerkinElmer, Waltham, MA)
with the following settings: isotropic voxel size of 10 μm, 70 kV, 160 mA, 5 mm field of view, 3
minute scan (FINE setting) per sample. Raw μCT images were processed using Quantum FX μCT
software (PerkinElmer). For the analysis of calcified tissue, the volume enclosing the entire 6-cm
aorta segment is selected. Images were segmented into calcified and non-calcified tissue on each
volume of interest using a global threshold method. After calibration and identification of
calcified tissue, the amount of calcium in the sample were quantified using the Quantum FX μCT
Software.

Aortic tissue sample preparation for LC-MS analysis
Tissue (300 mg for human and 50 mg for mice) was weighed and lyophilized to complete
dryness. Dried tissue samples of human (50 mg) and mice (10 mg) were taken for analysis. The
sample extraction procedure involved two steps. First, lipids and material not associated with
calcium domain were removed as follows: tissue samples were homogenized and extracted
sequentially, with 6 mL of chloroform and then 6 mL of methanol. Samples were vortexed well
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and centrifuged at 2500 rpm for 20 minutes. The supernatants were removed. Second, for
extraction of organic acids associated with calcium, the precipitation was incubated in methanol
(6 mL × 2) containing 10% acetic acid (HAc) at 45°C for 45 minutes, vortexed well, centrifuged at
2500 rpm and the supernatants were collected. Two extracts were combined and evaporated to
dryness under the gentle stream of nitrogen. The residues were dissolved in 500 µL of methanol
containing 0.1% formic acid. The samples were centrifuged at 12000 rpm for 20 minutes and
filtered through 0.22 µm PVDF syringe filters (Fisher Scientific, # 0992728A) for LC-MS/MS
analysis. For calcium and phosphate detection, samples were incubated in water containing 10%
HAc at 50°C for 1 hour, after the removal of lipids and materials that are not associated with
calcium.

LC-MS analysis
Samples were analyzed on Agilent 1200 series high performance liquid chromatography
(HPLC) (Agilent Technologies, CA, USA). The HPLC system consisted of G1379B degasser, G1311A
quaternary pump, HTC PAL autosampler and G1316A column compartment coupled to 6520B
hybrid quadrupole time-of-flight mass spectrometer (QTOF-MS) equipped with dual electrospray
ionization (ESI) source. Analytes were separated on PerkinElmer Brownlee SPP C18 (100 × 2.1
mm, L×ID, 2.7 µm PS, #N9308404) UHPLC column protected with C18 (5×2.1 mm, L×ID, 2.7 µm
PS, # N9308513) guard column. Binary mobile phase gradient program was used to separate the
molecules, pump-A: methanol and pump-B: water, both containing 0.1% (v/v) formic acid. The
linear gradient program was as follows: 0–8 minutes, 90% B; 8–25 minutes, 10% B; 25–38
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minutes, 10% B; 38-38.1; 90% B; 38.1–45 minutes 90% B. The column was operated at 45°C with
a constant mobile phase flow rate of 0.3 mL/minutes.
Data were acquired in ESI negative mode for identification of organic acids associated
with calcified domains. Mass spectral data were collected in the mass range of 20–1700 m/z, in
auto MS/MS mode to obtain MS and MS/MS data simultaneously. The mass spectrometer was
tuned at 4GHz high resolution mode at low 1700 m/z range with a manufacturer ESI-TOF
calibration solution (Agilent, #G1969-85000). To ensure good mass accuracy TOF reference mass
solution (Agilent, #G1969-85001) was continuously introduced via the second nebulizer
throughout the analysis. ESI source parameters were optimized and operated under the
following conditions: capillary voltage: 3.5 kV; source temperature: 320°C; nitrogen (N 2) used as
a drying and nebulizer gas: 12 L/minutes and 50 psig respectively, TOF parameters: Fragmentor
and skimmer voltages: 100 V and 65 V respectively. N2 used as a CID gas for MS/MS studies,
optimized collision energy (CE) set at 22 volts. The MS data were collected and processed using
Masshunter Qualitative Analysis Software Version B.07.00.
The presence of AzA was confirmed by its high resolution mass detected as deprotonated
molecular ion at m/z 187.0987 eluted at 16.95 (± 0.2). Also confirmed further by analyzing
authentic reference standard of AzA and MS/MS fragmentation spectral match with the
reference standard.
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Quantification of AzA
The developed LC-MS method was validated according to the FDA guidelines
(Bioanalytical method validation, guidance for Industry) for quantitative analysis of AzA in three
types of tissue samples (normal, diseased non-calcified and calcified tissues). Limit of detection
(LOD) and limit of quantifications (LOQ) were calculated in terms of signal to noise ratio (LOD,
S/N≥3 and LOQ, S/N≥ 10), were found to be 50 and 75 pmoles respectively. The linearity of AzA
is examined in matrix spiked and in neat solvent spiked samples at the concentration range of 75
to 5000 pmoles, using stable labeled isotope AzA-D14 as an internal standard (IS) at a constant
concentration of 250 pmoles. The calibration curves were graphed between the area under the
curve ratio of AzA/AzA-D14 against the concentration of AzA. The matrix spiked and neat solvent
calibration curves of AzA shown to be linear, with regression coefficients (R2) greater than 0.995.
Quality control sample were analyzed in triplicates (n=3) at three different concentrations 75,
150 and 300 pmoles to evaluate precision of the method in terms relative standard deviations (%
RSD), observed to be below 13%.

Matrix effect of tissue samples
Matrix effect (ME, %) of the method was determined by comparing response ratio of
analyte and IS (AzA/AzA-D14, AUC) in standard solution against with the matrix spiked standards
(33). ME was calculated at three different concentration levels, 75 (LOQ), 150 and 300 pmoles,
in triplicates (n=3) and found to be 10.13, 8.63 and 5.6 % respectively.
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Extraction recovery of AzA from tissues samples
Extraction recovery (ER, %) of AzA was calculated by pre extraction and post extraction
spikes of calcium-azelate (Ca-AzA). Blank matrix ensured that AzA was absent in tissue
extract/diluted matrix for matrix spiking experiments. Pre extraction spike: Ca-AzA added to the
tissue samples and stored at -80°C overnight, thawed the next day, homogenized and extracted
as described in sample preparation section. post extraction spike: Ca-AzA was added to the
acidified methanol tissue extract and incubated at 45°C for 30 minutes. ER carried out at three
different concentrations, 75 (LOQ), 150 and 300 pmoles in triplicates (n=3) and found to be 71.7,
76.7 and 81.2 % respectively.

Calcium and Phosphate quantification
Samples were prepared as described in methods; calcium and phosphate were quantified
using Abcam (Cambridge, MA) colorimetric assay kits, calcium colorimetric assay (ab102505) and
phosphate colorimetric assay (ab65622) following the instructions of supplier’s protocol.

Statistical analysis
Values are presented as a mean ±standard deviation (SD), and statistical analyses were
performed by using student’s t-test, with P<0.05 as the level of significance. For multiple group
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comparisons, one way ANOVA-Bonferroni multiple comparison test was used with p<0.05 as the
level of significance.
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Abstract
Atherosclerosis is a chronic inflammatory disease propagated by the deposition and
oxidation of lipids within blood vessels, with advanced disease states often resulting in
calcification. Lipid peroxides and their degradation products play an important role in the
pathogenesis of atherosclerosis. We have recently shown that lipid peroxide degradation
products including aldehydes and aldehyde-derived dicarboxylic acids are involved in the
formation of atherosclerotic calcification. In this study, we examine the expression of
inflammatory, oxidative, and calcifying markers in both calcified and non-calcified atherosclerotic
tissue, and compare this to expression levels in human aortic smooth muscle cells (HASMC) that
have been calcified by treatment with the dicarboxylic acid, azelaic acid (AzA). We isolated
calcified and non-calcified atherosclerotic lesions from human aortic tissue and from aged
apoE/PON1 double knockout mouse. Results indicated that AzA induces calcification
independent of osteoprotegrin, osteopontin, and alkaline phosphatase. Moreover, AzA calcified
cells express less inflammatory markers compared to untreated controls, indicating a unique and
perhaps beneficial type of calcification.
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Introduction
Atherosclerosis involves damage to intima, recruitment of inflammatory cells, lipid
accumulation, and may involve the eventual calcification of the lesion or plaque rupture [15].
Inflammation has been suggested to be a key mediator of many events during atherosclerosis
development [1, 100]. Vascular calcification is a major independent predictor of cardiovascular
morbidity and mortality [101]. Vascular smooth muscle cells express bone differentiation
markers such as alkaline phosphatase, which is suggested to provide phosphate for the formation
of calcium phosphate complexes. Macrophage-derived factors, such as transforming growth
factor-β (TGF- β), products of lipid peroxidation, and tumor necrosis factor-alpha (TNF-α), are
reported to enhance in vitro calcification of vascular cells [102]. It is believed that the
macrophage-lipid-rich early fatty streak lesions progress to extra-cellular lipid rich raised complex
lesions later in adult life with or without calcification [15, 59, 60]. While the extent of calcification
has been correlated with plaque burden, there has been a great deal of debate about the role of
calcification in plaque rupture [95-98]. Many researchers believe that coronary arterial
calcification may represent an attempt to protect the weakened atherosclerotic plaque prone to
rupture [42, 99]. Demer et al., and others have suggested that soft plaque surrounding areas of
calcification predisposes to plaque rupture [103, 104]. Neither the mechanism(s) involved in
atherosclerotic calcification nor the nature of the calcium deposits has been positively identified.
Calcification is identified mostly by von Kossa or alizarin red staining or by physical imaging
techniques such as computerized tomography [63-66]. While they give valuable information for
the presence of calcium, they do not indicate the chemical form in which calcium is deposited.
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Neither calcium phosphate precipitates nor Ca-bound sulfated proteoglycans could account for
lipid association. Recent studies also seem to suggest that calcified plaques are resistant to
rupture and vulnerable plaques are predominantly associated with non-calcified domains [105].
Calcification and inflammation are crucial pathological processes in atherosclerosis.
Recent study showed that genetic variations such as matrix inhibitory proteins, polymorphisms
for tumor necrosis factor and inﬂammatory cytokines might inﬂuence coronary calciﬁcation
[106]. This might be due to the ongoing oxidative process, which might play major role in the
generation of the vulnerable plaque, inﬂammatory cytokines and matrix disruption, release of
lytic lipids such as Lyso-PtdCho and aldehydes, release of reactive oxygen species, and proteolytic
enzymes. Further, these products inter-reactions and their involvements in calcification are yet
to be determined.
The breakdown of peroxidized lipids into aldehydes has been well documented in the
context of atherosclerosis (24). The oxidation of linoleic acid generates toxic and reactive
aldehydes which have been implicated in modiﬁcation of cellular proteins and other materials.
Aldehydes are extremely oxidation-labile and are readily converted into carboxylic acids.
Oxononanoic acid is one such aldehyde derived from the oxidation of linoleic acid, which is the
major component of LDL is of great biological signiﬁcance as it gets readily oxidized to AzA. Along
with this oxidation the modification of PtdCho on the oxidized LDL particle generates Lyso-PtdCho
species via the action of sPLA2. The oxidation of ONA to AzA is a simple oxidation step and is
mediated by both enzymatic (aldehydes oxidase, aldehyde dehydrogenase, MPO, xanthine
oxidase) as well as by nonenzymatic oxidation.
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AzA is used extensively as an anti-inflammatory ingredient in acne treatment [94]. It is
extremely well tolerated by animals and humans. The literature on AzA is scanty and we were
one of the first to point out to its formation from lipid peroxidation and its ability to reduce
atherosclerosis [25]. AzA would have two important anti-atherogenic properties: one, as other
dicarboxylic acids, it would have great affinity for calcium and sequester calcium in lipid-rich
domains [83, 84, 107]. This might account for the unusually high calcification associated with lipid
core domains. Second, AzA has been noted to have anti-inflammatory properties and has been
noted to decrease cytokine production by macrophages and inflammatory cells [85, 86]. It also
has been noted to reduce oxidant production by leukocytes [87].
Thus, identification of AzA as a calcium-binding lipid would explain the association of Ca
with lipid rich plaque and the association of calcification with the lipid peroxidation process. To
our knowledge, the proposed studies are the first to suggest a link between oxidative stress,
inflammation, calcification, and atherosclerosis.
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Methods
Reagents and Cell culture
Primers and Trizol reagent were purchased from Invitrogen (Carlsbad, CA). All other
routine chemicals were purchased from Sigma (St. Louis, MO). HASMC (ATCC) were cultured in
DMEM/F12 media supplemented with 10% fetal bovine serum (FBS).

Micelle Preparation
Azelaic acid (100 µM) was mixed with lysophosphatidylcholine (50 µM), vortexed well and
dried under gentle nitrogen flow. The dried mixture was re-suspended in aqueous media
generating Lyso-PtdCho/AzA micelles and used for treatment of cells.

Induction of calcification in HASMCs by AzA
HASMCs were grown in standard growth medium supplemented with either Lyso-PtdCho
(50 µM) alone, or with Lyso-PtdCho (50 µM) and AzA (100 µM) mixed micelles or with Na-AzA for
9 days. One set of cells was used to determine calcification by Alizarin red and van Kossa staining.
One set used to monitor the changes in genic expression involved in calcification as well as
inflammation related genes. Cells were harvested in Trizol for RNA isolation after 24 hours of
incubation.
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von Kossa Staining
After micelle treatment, cells were washed four times with PBS, and fixed in 10% formalin
for 30 minutes on ice. Formalin was aspirated and cells were washed three times with PBS,
followed by four washes with deionized water, and incubated with 1% silver nitrate for 4 hours
(2 hours under an ultraviolet light followed by 2 hours under a bright fluorescent lamp). Following
staining, silver nitrate solution was aspirated and the cells were washed with deionized water
once. To remove background and nonspecific deposits, cells were incubated with 5% sodium
thiosulfate solution for 2 minutes, followed by washing twice with deionized water. Slides were
mounted and imaged using Leica microscope. Calcium deposits can be visualized by dark brown
to black spots.

ApoE/PON1 double knockout Mice
ApoE/PON1 were developed using PON1(-/-) and ApoE(-/-) mice of C57BL/6J background
from Jackson Labs. Double knockouts were developed by crossing ApoE(-/-) mice with PON1(-/-)
mice for 12 generations. Mice were genotyped by polymerase chain reaction (PCR) of tail DNA,
as previously described. DNA was isolated from mouse tails by proteinase K treatment. PCR
genotyping was performed following the instructions of supplier’s protocol.
Twelve 18-month old male ApoE/PON1 mice weighing 30-38 g were used for this study.
The animals were regularly monitored and a weekly record of body weight was maintained up to
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2years. All procedures were performed according to protocol approved by The Institutional
Animal Care and Use Committee.

Collection of mouse plasma and organs
After 18 months, mice were fasted overnight and anesthetized with 1-2% isoflurane.
Fasting blood samples were collected into EDTA tubes by heart puncture. Plasma was separated
as described previously (35) and stored at -80°C.

Isolation and quantification of aortic lesions
Isolation of the aorta and quantification of aortic lesions was performed as described
previously (35-37). Lesion areas were marked on photographs. The lesion area was quantified
using ImageJ software (38). Calcified lesions in aortas were detected by using the IVIS Xtreme
imaging X-ray system. Calcified aortic lesions were identified and dissected from non-calcified
regions collected and saved for RNA isolation.

Isolation calcified and non calcified regions of the human aortic tissues
Following IRB approval control and Human calcified tissue samples were collected from
Collaborative human tissue network (CHTN). 11 pairs of samples were used for the current study.
Age, gender, pathology and disease severities of subjects were similar. Calcified tissues were
imaged using the IVIS Xtreme x-ray imaging system. Non-calcified and calcified regions were

81

identified and dissected, then reconfirmed by X-ray analysis. 100mg of sample was used for RNA
isolation.

Sample preparation for LC-MS analysis:
Frozen tissue samples were thawed and each 100 mg of tissue was taken for analysis.
Tissue samples were homogenized in presence of sterile sand thoroughly with mortar and pestle
by adding highly purified sand of about 150 mg. The extraction of analytes from tissue
homogenates involved first a modified Bligh and Dyer method of lipid extraction methanol:
chloroform : water (3 mL : 3 mL : 2.7 mL) and mixed well for 2 minutes by vortex mixer,
centrifuged at 2500 rpm for 20 minutes. The top aqueous layer and bottom organic phases were
separated and collected. The precipitation in the middle layer contained protein and other
insoluble material contained the calcified material. The precipitation was incubated in 2.7 mL of
4N HCl for 2 hours at 50 °C for dissociation of calcium salts, releasing any associated lipids from
calcified domains. The lipids were extracted by adding methanol : chloroform (3 mL : 3 mL),
vortexed for 2 minutes and centrifuged at 2500 rpm for 20 minutes. The bottom organic phase
was analyzed for organic acids and lipids by LC-MS.

LC-MS Analysis
Samples were analyzed on Agilent 1200 series high performance liquid chromatography
(HPLC) (Agilent Technologies, CA, USA). The HPLC system consisted of G1379B degasser, G1311A

82

quaternary pump, HTC PAL autosampler and G1316A column compartment coupled to 6520B
hybrid quadrupole time-of-flight mass spectrometer (QTOF-MS) equipped with dual electrospray
ionization (ESI) source. Analytes were separated on PerkinElmer Brownlee SPP C18 (100 × 2.1
mm, L×ID, 2.7 µm PS, #N9308404) UHPLC column protected with C18 (5×2.1 mm, L×ID, 2.7 µm
PS, # N9308513) guard column. Binary mobile phase gradient program was used to separate the
molecules, pump-A: methanol and pump-B: water, both containing 0.1% (v/v) formic acid. The
linear gradient program was as follows: 0–8 minutes, 90% B; 8–25 minutes, 10% B; 25–38
minutes, 10% B; 38-38.1; 90% B; 38.1–45 minutes 90% B. The column was operated at 45°C with
a constant mobile phase flow rate of 0.3 mL/minute.
Data were acquired in ESI negative mode for identification of organic acids associated
with calcified domains. Mass spectral data were collected in the mass range of 20–1700 m/z, in
auto MS/MS mode to obtain MS and MS/MS data simultaneously. The mass spectrometer was
tuned at 4GHz high resolution mode at low 1700 m/z range with a manufacturer ESI-TOF
calibration solution (Agilent, #G1969-85000). To ensure good mass accuracy TOF reference mass
solution (Agilent, #G1969-85001) was continuously introduced via the second nebulizer
throughout the analysis. ESI source parameters were optimized and operated under the
following conditions: capillary voltage: 3.5 kV; source temperature: 320°C; nitrogen (N2) used as
a drying and nebulizer gas: 12 L/minutes and 50 psig respectively, TOF parameters: Fragmentor
and skimmer voltages: 100 V and 65 V respectively. N2 used as a CID gas for MS/MS studies,
optimized collision energy (CE) set at 22 volts. The MS data were collected and processed using
Masshunter Qualitative Analysis Software Version B.07.00.
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The presence of AzA was confirmed by its high resolution mass detected as deprotonated
molecular ion at m/z 187.0987 eluted at 16.95 (± 0.2). Also confirmed further by analyzing
authentic reference standard of AzA and MS/MS fragmentation spectral match with the
reference standard.

Quantification of AzA
The developed LC-MS method was validated according to the FDA guidelines
(Bioanalytical method validation, guidance for Industry) for quantitative analysis of AzA in three
types of tissue samples (normal, diseased non-calcified and calcified tissues). Limit of detection
(LOD) and limit of quantifications (LOQ) were calculated in terms of signal to noise ratio (LOD,
S/N≥3 and LOQ, S/N≥ 10), were found to be 50 and 75 pmoles respectively. The linearity of AzA
is examined in matrix spiked and in neat solvent spiked samples at the concentration range of 75
to 5000 pmoles, using stable labeled isotope AzA-D14 as an internal standard (IS) at a constant
concentration of 250 pmoles. The calibration curves were graphed between the area under the
curve ratio of AzA/AzA-D14 against the concentration of AzA. The matrix spiked and neat solvent
calibration curves of AzA shown to be linear, with regression coefficients (R2) greater than 0.995.
Quality control sample were analyzed in triplicates (n=3) at three different concentrations 75,
150 and 300 pmoles to evaluate precision of the method in terms relative standard deviations (%
RSD), observed to be below 13%.
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Matrix Effect of Tissue Samples
Matrix effect (ME, %) of the method was determined by comparing response ratio of
analyte and IS (AzA/AzA-D14, AUC) in standard solution against with the matrix spiked standards
(30). ME was calculated at three different concentration levels, 75 (LOQ), 150 and 300 pmoles,
in triplicates (n=3) and found to be 10.13, 8.63 and 5.6 % respectively.

Extraction Recovery of AzA From Tissues Samples
Extraction recovery (ER, %) of AzA was calculated by pre extraction and post extraction
spikes of calcium-azelate (Ca-AzA). Blank matrix ensured that AzA was absent in tissue
extract/diluted matrix for matrix spiking experiments. Pre extraction spike: Ca-AzA added to the
tissue samples and stored at -80°C overnight, thawed the next day, homogenized and extracted
as described in sample preparation section. post extraction spike: Ca-AzA was added to the
acidified methanol tissue extract and incubated at 45°C for 30 minutes. ER carried out at three
different concentrations, 75 (LOQ), 150 and 300 pmoles in triplicates (n=3) and found to be 71.7,
76.7 and 81.2 % respectively.

ALP activity
50 mg of tissue samples were suspended in 1 mL of 2 mM Tris, 50 mM D-Mannitol
containing PMSF at 40 μg/5 mL followed by homogenization for 15 seconds on ice using a tissue
homogenizer. The homogenized suspension was then centrifuged at 1,000 rpm for 10 minutes at
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4°C in order to remove the nuclear membrane. The supernatant was transferred to a 1.5 mL
micro centrifuge tube. Protein concentration was quantified out using a Bio-Rad protein assay.
100 μg of total cellular protein was incubated with 200 µL freshly prepared substrate (7 mM pnitrophenyl phosphate, 0.1M sodium bicarbonate, 5mM magnesium chloride) for 20minutes at
37 °C. The reaction was then quenched by adding 0.1 M solution of sodium hydroxide and read
the absorbance at 410 nm was determined on 96-well plate spectrophotometer (Bio-Rad).

cDNA synthesis and RT-PCR reaction
Total RNA from cells and aortic tissue were isolated in Trizol reagent. Total RNA of 1 µg
was then reverse-transcribed into cDNA using the Superscript III First Strand Synthesis system
(Invitrogen, Carlsbad, CA). cDNA (50 ng) samples were used to perform Quantitative real time
PCR by iQTM5 iCycler Multicolor Real-Time PCR Detection System (Bio-Rad, Hercules, CA) with
SYBR Green (Invitrogen, Carlsbad, CA). Human oligonucleotide primers for RT-PCR were
purchased from Invitrogen (Carlsbad, CA). Polymerase chain reaction (PCR) was carried out with
OPN, OPG, MGP1, RANKL, MMP-9, ALPL, APLI, Catalase, SOD2, and MPO with mouse and human
specific primers, resulting in a 200bp fragment each. GAPDH was used as a reference gene. PCR
was performed with an initial step of denaturation at 50 °C for 2 minutes, 95 °C for 10 minutes
followed by 40 cycles of 95 °C for 20 seconds and 60 °C for 20 seconds. Melt curves were
established for the reactions. Normalized fold expression was calculated by using the 2-∆∆Ct
algorithm.
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Statistical analysis
A student’s t test was performed and values are presented as a mean ± standard deviation
(SD), with P<0.05 as the level of significance. Significance between groups was calculated by using
two tailed student’s t-test and Wilcoxon matched paired test using Prism Pad software, with
P<0.05 considered significant. For multiple group comparisons, a one way ANOVA- Bonferroni
multiple comparison test was used with P<0.05 as the level of significance.
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Results
Calcification of Human Aortic Smooth Muscle Cells
First, it was necessary to induce calcification of Human Aortic Smooth Muscle Cells
(HASMC). To accomplish this, HASMC were grown in standard growth medium to confluence then
were treated with Lyso-PtdCho/AzA (50 μM/100 μM) mixed micelles for 9 days as described
previously [108]. β-glycerophosphate was used as a positive control for calcification. Calcification
was assessed using von Kossa staining as shown in Figure 1. Unstained cells were used for genetic
analysis.

Figure 17 – Calcification of HASMC

HASMC were treated for 9 days and calcification was visualized via von Kossa staining. Calcium
deposits appear as dark brown-black spots.
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Effect of AzA induced calcification on HASMC genetic expression
First we analyzed genes that inhibit calcification, osteoprotegerin (OPG), osteopontin
(OPN), matrix Gla protein (MGP1), and matrix metallopeptidase (MMP9). Interestingly we found
that AzA-induced calcification has an inhibitory role on them as shown in Figure 2A.
Interestingly, AzA-induced calcification reduced expression of the inflammatory tumor
necrosis factor -α (TNF-α), interleukin 1β (IL-1β), and myeloperoxidase (MPO) as shown in Figure
2B. Surprisingly AzA treatment also resulted in the expression levels of the calcification
promoters receptor activator of nuclear factor kappa-Β ligand (RANKL), and two isoforms of
alkaline phosphatase liver (ALPL) and intestinal (ALPI), Figure 2C. This may indicate a unique
method of calcification of HASMC via AzA treatment. Expression of genes related to oxidative
stress catalase and Superoxide dismutase 2 (SOD2) enzymes were also reduced as shown in
Figure 2D.
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Figure 18 – Genetic Profile of AzA induced Calcification

Expression of genes in HASMC calcified via AzA treatment. A. Calcification inhibitors. B.
Inflammatory genes C. Pro-calcification markers. D. Oxidative stress markers.

AzA induced calcification of HASMC inhibits alkaline phosphatase activity
In addition, alkaline phosphate activity on the cell lysate of calcified cells, surprisingly the
activity was decreased, suggesting that the induction of calcification in a process independent
this enzyme. ALP activity increases the local concentration of free phosphate allowing for
formation of a calcium phosphate complex, suggesting that AzA mineralization
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Figure 19 – Alkaline Phosphatase Activity

Alkaline phosphatase activity of cell lysate of calcified HASMC treated with AzA.

Expression of genes related to calcification in human and mouse aortic samples
We analyzed the expression of the calcification inhibitors (OPG, OPN, and MGP1),
inflammatory genes (TNF-α, IL-1β, MPO), calcification promoters (RANKL and ALP), and oxidative
stress (catalase and SOD2) in aged (2 year old) ApoE/PON1 double knockout mouse aortic tissues
as shown in Figure 4. In order to compare genetic expression of normal, non-calcified
atherosclerotic, and calcified atherosclerotic tissue samples, x-ray analysis was performed
calcified domains were dissected from the non-calcified atherosclerotic tissue as shown in Figure
5. AzA was also quantified in these human samples. Expression levels of genes of interest were
compared as shown in Figure 6.
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Figure 20 – ApoE/PON1 DKO Gene Expression in Calcified and Non-Calcified Aortic Lesions

Aged (2 year old) ApoE/PON1 DKO mice calcified and non-calcified atherosclerotic lesions
were compared to control (wild type 2 year old mice). Genetic expression for genes related to A.
Calcification inhibitors. B. Inflammation, and C. Oxidative stress markers.
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Figure 21 – Detection of Calcification and AzA in Human Aortic Tissue

Identification of calcified domains in human aortic tissue samples. A. Normal, noncalcified atherosclerotic lesions, and calcified atherosclerotic lesions were identified and
dissected using x-ray analysis. B. Quantification of AzA was performed using LC-MS analysis.
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Figure 22 – Expression Levels in Human Aortic Tissue

Human aortic tissue expression levels were determined for control (non-atherosclerotic
aorta), non-calcified atherosclerotic lesions, and calcified atherosclerotic lesions. Genetic
expression for genes related to A. Calcification inhibitors. B. Inflammation, C. Calcification
promoters, and D. Oxidative stress markers.
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Discussion
Oxidative stress has been implicated in atherosclerosis and in many associated risk
factors. The effects of lipid peroxides and their aldehydes breakdown products on atherosclerosis
have been studied extensively. Aldehydes such as malondialdehyde (MDA) and 9-oxononanoic
acid (ONA) are chemically unstable intermediates and are readily oxidized to carboxylic acids,
such as malonic acid, and AzA. In addition to spontaneous oxidation, a variety of enzymes and
processes are capable of converting aldehydes into carboxylic acids. We have recently shown
that AzA plays a role in atherosclerotic calcification [108].
AzA has been shown to display anti-inflammatory and anti-atherosclerotic properties
[25]. This along with our recent findings led us to study the implications it may have on
inflammation within the calcified lesion. MPO’s potential involvement in atherosclerosis has
gained tremendous importance in recent years. It has been shown that macrophages in human
atherosclerosis contain MPO, suggesting that MPO might play a special role in pathogenesis of
atherosclerosis [109-111]. Recent pioneering studies showed that MPO-derived products are
elevated in subjects with CVD. Using state-of-the-art methodologies, MPO-derived biomarkers
have been noted to be present in increasing concentrations in subjects with coronary artery
diseases. These products include nitrated, chlorinated or cross-linked tyrosine residues, as well
as products of lipid peroxidation and changes in the amino groups of amino acids [112]. Studies
have also shown that MPO contributes considerably to plaque vulnerability. The results of these
studies also suggested the importance of the predictive value MPO in the absence of circulating
troponins, as this suggests that MPO release actually precedes myocardial infarction and
95

identifies patients with unstable plaques before complete microvascular obstruction. Our studies
suggest the decreased MPO in regions calcified by AzA treatment may be beneficial and play a
role in increasing plaque stability and disease progression.
Conflicts exist in between human and animal studies data of MPO and atherosclerosis. It
has been identified that the irradiation of LDLR knockout mice followed by subsequent infusion
of MPO knockout mice’s bone marrow significantly increased the atherosclerotic lesions.
Similarly, MPO-knockout in apolipoprotein E knockout mouse model also did not show any
impact on atherosclerosis development. Furthermore, murine leukocytes were identified to carry
a less amount of MPO per cell as compared with corresponding human leukocyte types. There is
also evidence that specific MPO gene regulatory elements may be missing in mouse MPO. In
contrast, studies showed that when human MPO was over expressed in mice, there was a
marginal but significant increase in atherosclerosis. While the MPO concentration and genetics
might play a role in the atherosclerotic susceptibility of mice, it also needs to be kept in mind that
rodent atherosclerosis development is an accelerated model of atherosclerosis. MPO’s
involvement might be at very early stages of atherosclerosis when oxidation is initiated. Nonspecific propagation of oxidation might overwhelm the disease process under such conditions,
particularly when other pathways of oxidation have been noted to be important. In view of
conflicting results on the effect of MPO in human and animals, care should be taken to draw a
definitive conclusion whether to aggressively approach for anti-MPO therapy in the
atherosclerosis treatment.
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Another major difference between human and animal atherosclerosis is the contribution
of inflammatory cytokines and matrix digesting enzymes (MMPs) to the advancement of the
vulnerable plaque [111, 113, 114]. Most of these cytokines and MMPs are induced by oxidative
stress suggesting that ongoing oxidative processes might be involved in the generation of the
vulnerable plaque. Matrix disruption coupled with the release of inflammatory cytokines, lytic
lipids (Lyso-PtdCho), aldehydes, reactive oxygen species, and proteolytic enzymes have been
suggested to play major roles in plaque vulnerability and rupture.
Decreased expression of antioxidant genes such as catalase and SOD was observed,
suggesting that this may be due to PPAR signaling pathways [110, 115]. The results also suggest
increased oxidative stress in calcified lesions is due to reduction in expression and activity of
these antioxidant enzymes as compared to control and non-calcified lesions.
Alkaline phosphatase (ALP) is a bone-related molecule; it is involved in the formation of
mineralized bone-like structures along with type-I collagen (ColI) and osteocalcin (OC) [62, 84,
88, 96]. Its downregulation due to AzA treatment provides further evidence that AzA induces
calcification in a unique ALP-independent manner.
These results of characterize calcification induced by AzA treatment and highlight the fact
that atherosclerotic calcification is a heterogeneous process involving inflammatory and
oxidative processes. Future studies delineating the balance between these will provide insight on
how to enhance therapeutic strategies in the treatment of atherosclerosis. Studies on the
differences between human and mouse models will also enhance the efficient utilization of
atherosclerotic animal models in studying disease progression and its early detection.
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Understanding the interplay of inflammatory and oxidative markers is an important precursor to
the development of new diagnostic tools for early atherosclerosis.
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CHAPTER FIVE: CONCLUSION
Atherosclerosis is a diseased characterized by the accumulation of lipids within vessel
walls, their subsequent exposure to oxidative stresses leading to the formation of lipid peroxides
and degradation products which further promote inflammation. As the lipids undergo oxidation
they degrade into molecules which are more deleterious than their precursors, aldehydes, which
are highly reactive and cytotoxic. We demonstrated this degradation cascade process in cell
culture models; the incubation of HASMC with HPODE resulted in detection of ONA, which was
then further oxidized into AzA. The conversion of ONA to AzA was inhibited by antioxidant αtocopherol, indicating that it was an oxidative pathway. This alone was a fascinating finding that
illustrated the circular nature of the disease pathway, that the same oxidative stress that initiates
atherogenesis is able to detoxify the final and perhaps most cytotoxic products.
While it has been established that aldehydes formation is a result of decomposition of
lipid peroxides, their oxidation to carboxylic acids and their ability to form mineralized complexes
have been overlooked. This is the first study to demonstrate the ability of AzA to bind calcium
and form an insoluble complex. Moreover, the calcium azealate complex was only formed when
azelaic acid was delivered intracellularly as it cannot transverse the cell membrane due to its
dicarboxylic nature. AzA is able to enter cells in vivo due to the chemical nature of ONA, as
aldehydes readily cross the cell membrane, then are converted into AzA in the cytoplasm.
AzA provides anti-inflammatory and cardioprotective properties, yet it induces
atherosclerotic calcification. In the clinical setting, a patients coronary arterial calcification is an
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indication of overall cardiovascular health and indicative of a future cardiovascular event [69].
However the occurrence of those cardiovascular events, formation of a thrombus typically occurs
at vulnerable plaques. Calcified plaques are considered stable, as demonstrated by studies
reporting under 15% of ruptured human atherosclerotic lesions occur in calcified domains [23].
This stability results in an increased risk of rupture at the interface between the calcified and
vulnerable domains, as calcification results in further loss of elasticity of the vessel [116].
This is the first study that demonstrated a role for lipid peroxide derived DCA in
calcification, suggesting their terminal oxidation products may be involved in the generation of
calcium deposits. This is the first study to detect medium chain DCA in the calcium deposits of
human atherosclerotic lesions. AzA is not a normal molecule synthesized in the body. It is
absorbed from the diet or is the result of de novo oxidation of aldehydes to DCA. Interestingly,
AzA-induced calcification occurs independent of the expression of pro-calcifcation factors RANKL
and ALP. This may indicate that the presence of AzA is enough to facilitate the chemical binding
with calcium, in contrast to ALP mediated calcification where phosphate is generated and
concentrated enzymatically. This highlights the heterogeneous nature of calcification, provides
basis for the clinical treatment strategies, and emphasizes the importance of avoiding broad
therapeutic approaches in future studies.
Other lipids may be involved in the formation of calcified complexes. During our LC-MS
analysis we discovered several other peaks upon extraction of the decalcified homogenate. Other
carboxylic acids may be involved, along with phospholipids which are present in the lesion from
the oxidation of LDL. Phospholipids may also explain the presence of phosphate in the calcified
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material. The stoichiometry of the calcium and phosphate concentrations suggest that additional
molecules are necessary to bind the calcium released during acid hydrolysis of the calcified
mineral. Phospholipids may explain the source of this phosphate, as there are phospholipases
present in the atherosclerotic plaque. Alternatively, perhaps the intact phospholipids may
interact with the calcium with their phosphate group while providing the lipophilicity necessary
to associate with the fatty core.
To date, calcification is detected via physical techniques involving of x-rays, where the
calcium’s density inhibits the radiation from passing, or by chemical means of staining the calcium
component of the mineralized salt using specific dyes (i.e. xylenol orange) and stains (i.e. alizarin
red s). Thus the chemical structure, specifically, the molecule bound with calcium has been
overlooked in studies, and it was deduced that calcification in the context of atherosclerosis was
calcium phosphate in the form of hydroxyapatite due to similarities of osteocytes with progenitor
cells of smooth muscle cells [117]. That hypothesis does not fully explain how calcification is
associated with the lipophilic core of advanced plaques. This project was the first to challenge
the paradigm that atherosclerotic calcification exclusively consists of calcium phosphate by
providing evidence that AzA, a lipid associated molecule accumulates in the plaque and promotes
mineralization. Our conclusions are compatible with previous hypothesis, however, as calcium
azelate may be present along with diverse chemical complexes including other calcium-lipid
complexes, and inorganic complexes such as calcium phosphate.
The findings in this study may explain the failure of antioxidant trials in treating late stage
human atherosclerosis. Antioxidant studies have not only failed, but in some cases have
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exasperated late stage atherosclerosis. The goal of antioxidant treatment is to prevent the
further formation of lipid peroxides from unsaturated fatty acids, however untargeted
antioxidant treatment causes accumulation of aldehyde degradation products resulting in the
accumulation of these cytotoxic, pro-inflammatory, and highly reactive species resulting in
promotion of plaque vulnerability, as illustrated in Figure 23. These aldehydes are detoxified by
their further oxidation into their corresponding carboxylic acids, some of which (i.e. AzA) actually
provide an anti-inflammatory and anti-atherogenic effect. Perhaps the formation of AzA from
ONA may represent a protective mechanism to thwart plaque vulnerability in advanced disease
by promoting stability.

Figure 23 – Flowchart of Lipid Peroxide Degradation and Inhibition by Antioxidants
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Lipid peroxide decomposition products include hydroxides, aldehydes, and dicarboxylic
acids. While antioxidants (AO) inhibit the conversion of unsaturated fatty acids into lipid
peroxides, they also inhibit the oxidation of aldehydes into dicarboxylic acids.

Collectively this project, in addition to being combined with our findings that AzA
prevented atherosclerosis without affecting lipid levels and decreased CD68 positive
macrophages in the lesions, suggests that AzA induced calcification may be a protective measure,
where the oxidative stress is used in order to prevent further damage and vulnerability. This work
underscores the importance of targeted antioxidant therapy in late stage atherosclerosis, and
future studies on discovery of antioxidants that are specific to polyunsaturated fatty acids
coupled with an oxidant specific to aldehyde groups may provide both protection and
detoxification to those with advanced atherosclerotic plaques.
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writing to the IACUC for approval. Changes should not be initiated until written IACUC approval is
received. Adverse events should be reported to the IACUC as they occur.
If the protocol is over three years old, it must be rewritten and submitted for IACUC review and approval.
A renewal must be submitted for approval at least three months prior to the anniversary date of the most
recent approval.
This letter does not serve as Environmental Health and Safety (EHS) approval. EHS approval must be
handled separately. EHS approval must be obtained prior to initiating animal use or procedures that need
EHS approval. The contact phone number is 407-823-6300
Should you have any questions, please do not hesitate to call the office of Animal Welfare at (407) 882-1164.
Please accept our best wishes for the success of your endeavors.
Best Regards,

Cristina Caamaño
Associate Director, Research Program Services
Office of Research and Commercialization
Copies: Appropriate Facility Manager (when applicable)
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THE UNIVERSITY OF CENTRAL FLORIDA
INSTITUTIONAL ANIMAL CARE and USE COMMITTEE (IACUC)
Approval to Use Animals

Dear Dr. Sampath Parthasarathy,
Your application for IACUC Approval has been reviewed and approved by the UCF IACUC
Reviewers.
Approval Date:

8/17/2017

Title:

Double Knockout Mice Using LDLR-/-, PON1-/-, and APOE-/Combinations for Measuring the Aldehydes and Di-Carboxylic
Acid Role in Atherosclerosis

Department:

Burnett School of Biomedical Sciences

Animal Project #: 17-39
Expiration:

8/17/2018

You may purchase and use animals according to the provisions outlined in the above
referenced animal project.

Deborah Altomare, Ph.D.
IACUC Chair

Contact: Cristina Caamaño, Associate Director, Research Program Services Email:ccaamano@ucf.edu
Phone: (407) 882-1164 Fax: (407) 823-3299
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University of Central Florida Institutional Review Board
Office of Research & Commercialization
12201 Research Parkway, Suite 501
Orlando, Florida 32826-3246
Telephone: 407-823-2901, 407-882-2012 or 407-882-2276
www.research.ucf.edu/compliance/irb.html

From :

UCF Institutional Review Board #1
FWA00000351, IRB00001138

To

Sampath Parthasarathy

:

Date :

May 01, 2014

Dear Researcher:
On 5/1/2014 the IRB determined that the following proposed activity is not human research as defined by
DHHS regulations at 45 CFR 46 or FDA regulations at 21 CFR 50/56:
Type of Review:
Project Title:
Investigator:
IRB ID:
Funding Agency:
Grant Title:
Research ID:

Not Human Research Determination
Role of aldehyde oxidation in atherosclerosis
Sampath Parthasarathy
SBE-14-10275
National Institutes of Health( NIH )
Role of aldehyde oxidation in atherosclerosis
1053566

University of Central Florida IRB review and approval is not required. This determination applies only to the
activities described in the IRB submission and does not apply should any changes be made. If changes are to be
made and there are questions about whether these activities are research involving human subjects, please
contact the IRB office to discuss the proposed changes.
On behalf of Sophia Dziegielewski, Ph.D., L.C.S.W., UCF IRB Chair, this letter is signed by:

Signature applied by Joanne Muratori on 05/01/2014 10:23:00 AM EDT

IRB Coordinator
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